Tag: breast cancer

Sixty Percent of HR+/HER2- Breast Cancer Patients Who Progress on CDK4/6 Inhibitors Have PIK3CA Wild-Type Disease. Until Now, They Had No Approved Targeted Therapy. Revtorpyk Just Changed That.

The essentials: On July 14, 2026, the FDA approved Revtorpyk (gedatolisib, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib (Ibrance), for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation (PIK3CA wild-type), following progression on or after at least one line of endocrine therapy in the metastatic setting. Revtorpyk is the first FDA-approved multi-target PI3K/AKT/mTOR (PAM pathway) inhibitor, and the first targeted therapy approved for PIK3CA wild-type HR+/HER2- advanced breast cancer. What “PIK3CA wild-type” means and why it matters: approximately 40% of HR+/HER2- breast cancers carry activating PIK3CA mutations, for which alpelisib (Piqray) is approved. The remaining approximately 60% have PIK3CA wild-type disease, meaning no activating PIK3CA mutation is detected. This larger population has had no approved targeted inhibitor of the PI3K pathway because existing approved agents (alpelisib, inavolisib) require a PIK3CA mutation for indication. Gedatolisib works across both PIK3CA mutant and wild-type disease by targeting the pathway more comprehensively than PI3K-alpha-specific inhibitors. Mechanism: gedatolisib is a potent, pan-PI3K and mTORC1/2 inhibitor that blocks all four class I PI3K isoforms (alpha, beta, delta, gamma) plus both mTOR complexes simultaneously, providing comprehensive PAM pathway suppression that cannot be bypassed through isoform switching or mTOR feedback loops that limit single-target inhibitors. Administration: intravenous infusion over 30 minutes on days 1, 8, and 15 of a 28-day cycle. Lyophilized powder reconstituted before administration. The clinical basis: VIKTORIA-1 Study 1 (NCT05501886), Phase 3, open-label, randomized. PIK3CA wild-type cohort results published in JCO in March 2026. Median PFS: 9.3 months (gedatolisib plus palbociclib plus fulvestrant, triplet) versus 2.0 months (fulvestrant monotherapy); HR 0.24 (95% CI 0.17 to 0.35); p less than 0.001. 76% reduction in risk of progression or death with the triplet. Median PFS: 7.4 months (gedatolisib plus fulvestrant, doublet) versus 2.0 months; HR 0.33 (95% CI 0.24 to 0.48); p less than 0.001. 67% reduction in risk of progression or death with the doublet. ORR: approximately 32% (triplet) and 28.3% (doublet) versus approximately 1% (fulvestrant). Median DOR: 11.4 months (triplet) and 12.0 months (doublet). Regulatory pathway: NDA submitted November 2025 under the Real-Time Oncology Review (RTOR) program; Priority Review granted January 2026; Breakthrough Therapy Designation and Fast Track Designation previously granted. PIK3CA mutant indication: an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2- breast cancer is planned for Q3 2026 submission, based on the PIK3CA-mutant cohort of VIKTORIA-1 (Study 2), presented at ASCO 2026.

HR-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, accounting for approximately 70% of all advanced cases. The treatment landscape has been transformed over the past decade by CDK4/6 inhibitors paired with endocrine therapy, which have extended median survival to several years for many patients. But the disease almost always progresses, and what comes after CDK4/6 inhibitor-based treatment is one of the most actively contested questions in breast oncology.

The PI3K/AKT/mTOR pathway is one of the most important drivers of endocrine resistance in HR+ breast cancer. Activating mutations in PIK3CA, the gene encoding the PI3K alpha catalytic subunit, are present in approximately 40% of HR+/HER2- tumors and lead to constitutive PI3K activation that drives cell proliferation regardless of hormone availability. For this 40%, alpelisib (Piqray) provides an approved PI3K-alpha-specific targeted option.

But 60% of HR+/HER2- breast cancers have PIK3CA wild-type disease. No activating mutation. No approved PI3K-directed targeted therapy. Until July 14, 2026.

Revtorpyk (gedatolisib, Celcuity Inc.) is the first drug approved for this population, and its approval rests on a biological insight that distinguishes it from every prior PI3K inhibitor: the PAM pathway drives endocrine resistance not only when PIK3CA is mutated but across the broader population, and blocking the pathway comprehensively rather than at a single node produces clinical benefit even in the absence of a defining mutation. The Phase 3 VIKTORIA-1 data in PIK3CA wild-type patients, with a 76% reduction in risk of progression with the triplet regimen versus fulvestrant monotherapy, are among the most striking efficacy numbers produced in post-CDK4/6 inhibitor breast cancer trials to date.

The HR+/HER2- Treatment Landscape After CDK4/6 Inhibitor Progression

HR-positive, HER2-negative breast cancer is driven primarily by estrogen receptor signaling. Endocrine therapy blocks this signaling, and the addition of CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) to endocrine therapy has produced median progression-free survival of 25 to 30 months or more in the first-line metastatic setting, a major advance over endocrine therapy alone.

After CDK4/6 inhibitor-based first-line therapy progresses, the standard approach depends on disease characteristics. For patients with ESR1 mutations (which develop in approximately 30 to 40% of patients on aromatase inhibitor-based therapy), elacestrant (Orserdu) or other agents targeting mutant ESR1 are options. For patients with PIK3CA mutations, alpelisib (and more recently inavolisib) provide PI3K-directed options. For patients with BRCA1/2 mutations, PARP inhibitors are relevant.

The PIK3CA wild-type population, approximately 60% of all post-CDK4/6 inhibitor HR+/HER2- patients, has had none of these mutation-matched targeted options. The available treatments are additional endocrine therapy combinations, everolimus (mTOR inhibitor)-based regimens, and increasingly antibody-drug conjugates like sacituzumab govitecan. Everolimus specifically targets mTORC1 in isolation, and its clinical benefit in this setting has been partial, limited by the feedback reactivation of PI3K that occurs when mTORC1 alone is blocked.

Gedatolisib’s approval provides this population’s first approved targeted inhibitor of the PAM pathway.

The Science: Why Pan-PI3K Plus Dual mTOR Inhibition Is Mechanistically Different

The PI3K/AKT/mTOR pathway is a master regulator of cell growth, survival, and metabolism. Its dysregulation is among the most common events in human cancer. In HR+ breast cancer, the pathway drives endocrine resistance through multiple mechanisms: it activates estrogen receptor independently of ligand, promotes cell cycle re-entry through CDK4/6 activation, and drives antiapoptotic signaling that keeps tumor cells alive despite endocrine blockade.

The pathway architecture is a cascade: growth factor signals activate PI3K (which phosphorylates PIP2 to PIP3), which activates AKT, which activates mTORC1 and mTORC2, which drive downstream transcription and protein synthesis for proliferation and survival. The cascade also includes a critical negative feedback loop: mTORC1 inhibition (as produced by everolimus) triggers PI3K reactivation through relief of the S6K1-IRS-1 feedback, partially undercutting the intended therapeutic effect.

Gedatolisib addresses the pathway comprehensively:

All four class I PI3K isoforms (alpha, beta, delta, gamma): In PIK3CA wild-type disease, other PI3K isoforms (PI3K-beta particularly) can compensate when PI3K-alpha alone is blocked by an alpha-specific inhibitor. By blocking all four isoforms simultaneously, gedatolisib prevents isoform switching that would otherwise allow the pathway to remain active.

Both mTOR complexes (mTORC1 and mTORC2): mTORC2 phosphorylates AKT at Ser473, maintaining AKT activity even when upstream PI3K is partially inhibited. By blocking mTORC2 as well as mTORC1, gedatolisib closes the reactivation loop that limits the efficacy of mTORC1-selective inhibitors like everolimus.

The result is a mechanistic approach that suppresses the PAM pathway more completely and more durably than any single-target inhibitor, and that does so regardless of which specific mutation (or absence of mutation) is driving pathway activation. This is why gedatolisib produces clinical benefit in PIK3CA wild-type patients, where no single-node inhibitor has succeeded: the wild-type pathway remains abnormally activated through other mechanisms (receptor tyrosine kinase signaling, loss of PTEN, AKT mutations), and comprehensive blockade addresses these regardless of which upstream event is present.

Dr. Sara Hurvitz, principal investigator for VIKTORIA-1, stated that the trial validates the PAM pathway as a molecular driver in HR+/HER2- advanced breast cancer regardless of PIK3CA mutation status, meaning the approach of comprehensive pathway blockade is supported across the full population rather than requiring a specific mutation.

Why PIK3CA wild-type disease still has an active PAM pathway The intuition that PIK3CA wild-type disease lacks meaningful PI3K pathway activation is incorrect. Multiple mechanisms drive abnormal PAM pathway activity without a PIK3CA mutation: overactivation of receptor tyrosine kinases (HER3, IGF-1R, FGFR) that signal through PI3K; loss of PTEN (the phosphatase that opposes PI3K activity), present in 15 to 30% of HR+ breast cancers regardless of PIK3CA status; activating mutations in AKT1 or other pathway components; and post-CDK4/6 inhibitor adaptive changes that upregulate pathway activity as a resistance mechanism. Gedatolisib’s clinical activity in PIK3CA wild-type disease confirms that the pathway is biologically active and targetable in this population even without a defining PIK3CA mutation.

The VIKTORIA-1 Study 1 Trial: Full Data for the Wild-Type Cohort

Design

VIKTORIA-1 (NCT05501886) is a Phase 3, multicenter, open-label, randomized trial with two independently powered cohorts: Study 1 (PIK3CA wild-type) and Study 2 (PIK3CA-mutant). The two cohorts were analyzed separately. The approval and this post cover Study 1.

Study 1 enrolled adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA wild-type disease (no activating PIK3CA mutation detected by an FDA-authorized companion diagnostic assay) who had progressed on or after at least one line of endocrine therapy in the metastatic setting. The vast majority of enrolled patients had received prior CDK4/6 inhibitor-based therapy.

Patients were randomized 1:1:1 to three arms:

Gedatolisib plus palbociclib plus fulvestrant (triplet arm)
Gedatolisib plus fulvestrant (doublet arm)
Fulvestrant monotherapy (control arm)

Gedatolisib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day cycle. Palbociclib was given at 125 mg orally on days 1 to 21 of each cycle. Fulvestrant was given at standard dosing (500 mg IM on days 1 and 15 of cycle 1, then day 1 of each subsequent cycle). The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) in each gedatolisib-containing arm versus fulvestrant. Results were published in the Journal of Clinical Oncology in March 2026.

Primary efficacy results at median follow-up 12.8 months

Endpoint	Gedatolisib triplet	Gedatolisib doublet	Fulvestrant
Median PFS (BICR)	9.3 months	7.4 months	2.0 months
Hazard ratio versus fulvestrant	0.24 (95% CI 0.17 to 0.35)	0.33 (95% CI 0.24 to 0.48)	Reference
p-value versus fulvestrant	p less than 0.001	p less than 0.001	—
Risk reduction in progression or death	76% (triplet)	67% (doublet)	—
PFS incremental improvement	7.3 months	5.4 months	—

Source: Hurvitz SA et al. VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in HR+/HER2-/PIK3CA wild-type advanced breast cancer. JCO. 2026. doi:10.1200/JCO-25-02643. NCT05501886.

The magnitude of these PFS improvements is exceptional for the post-CDK4/6 inhibitor setting, where standard second-line endocrine combinations typically produce median PFS of 4 to 6 months. A median PFS of 9.3 months for the triplet and 7.4 months for the doublet, compared to 2.0 months for fulvestrant alone, represents a clinically dramatic separation of the curves. The control arm median PFS of 2.0 months reflects the biological reality of post-CDK4/6 inhibitor PIK3CA wild-type disease: fulvestrant monotherapy provides very limited benefit in this setting, confirming the extent of endocrine resistance and the unmet need.

Response and durability

Endpoint	Gedatolisib triplet	Gedatolisib doublet	Fulvestrant
Objective response rate (ORR)	Approximately 32%	28.3%	Approximately 1%
Median duration of response (DOR)	11.4 months	12.0 months	Not determinable (only 1 response)

The ORR of approximately 32% for the triplet and 28% for the doublet versus approximately 1% for fulvestrant reflects a real tumor-shrinking activity in a population where endocrine monotherapy produces almost no responses. The durability of approximately 11 to 12 months in responders is consistent with meaningful clinical benefit.

VIKTORIA-1 Study 2: The PIK3CA-Mutant Data at ASCO 2026

Though the July 14, 2026 approval covers only the PIK3CA wild-type population based on Study 1, Celcuity presented the PIK3CA-mutant cohort (Study 2) results at the 2026 ASCO Annual Meeting as a late-breaking abstract (LBA1008). The data showed statistically significant and clinically meaningful PFS improvements with both gedatolisib combinations versus standard of care in PIK3CA-mutant patients as well, with hazard ratios in the same directionally strong range as the wild-type cohort. An sNDA for the mutant indication is planned for Q3 2026 submission. This means gedatolisib, if that sNDA is approved, will ultimately cover the full HR+/HER2- post-endocrine therapy population regardless of PIK3CA mutation status, making mutation testing a guide to which comparator benchmark to use rather than a gating criterion for eligibility.

The VIKTORIA-1 Study 1 Design: What Makes the Control Arm Comparison Meaningful

One important interpretive context for the VIKTORIA-1 data: the control arm is fulvestrant monotherapy, not an active CDK4/6 inhibitor combination or another targeted agent. This is an appropriate and clinically grounded comparator for the post-CDK4/6 inhibitor PIK3CA wild-type setting, where physicians currently have no approved targeted option beyond fulvestrant. But it means the absolute PFS numbers should be interpreted as comparison to the current clinical standard (fulvestrant) rather than to other active agents that are also used in this setting.

No head-to-head trial has compared gedatolisib directly to other agents used in this line (such as sacituzumab govitecan or everolimus/exemestane). Those comparisons will emerge from clinical experience and real-world data over time.

Dosing and Administration

Revtorpyk is supplied as a lyophilized powder that requires reconstitution before administration. This manufacturing form reflects the formulation chemistry needed to maintain stability of the compound; it is reconstituted by pharmacy personnel and administered to the patient as a ready-to-use infusion.

Dosing schedule:

Gedatolisib: reconstituted and administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day cycle
Palbociclib (in the triplet): 125 mg orally once daily on days 1 to 21 of each 28-day cycle, with 7 days off
Fulvestrant (in both regimens): 500 mg IM on days 1 and 15 of cycle 1, then day 1 of each subsequent cycle

The weekly infusion schedule (3 infusions per 4-week cycle) is the most notable practical consideration for patients. This is more frequent clinical contact than the every-2-to-3-week infusion schedules of some other IV-administered oncology drugs, and it represents a meaningful time commitment for patients managing advanced breast cancer. The 30-minute infusion duration is relatively short compared to some IV biologics, but the weekly schedule means patients visit an infusion center three times every four weeks indefinitely.

PIK3CA testing requirement:

The approved indication specifies PIK3CA wild-type disease, meaning testing to confirm the absence of an activating PIK3CA mutation is required before initiating treatment. An FDA-authorized companion diagnostic assay must be used. This is a companion diagnostic requirement that should be incorporated into the workup for all patients with HR+/HER2- advanced breast cancer progressing on CDK4/6 inhibitor therapy, both to confirm gedatolisib eligibility and to identify the approximately 40% of patients who may instead be eligible for alpelisib, inavolisib, or the future PIK3CA-mutant gedatolisib indication.

Safety: The VIKTORIA-1 Profile

The safety profile of gedatolisib in VIKTORIA-1 is consistent with the known class effects of PAM pathway inhibition, with stomatitis and hyperglycemia as the most pharmacologically characteristic adverse events, and neutropenia as the dominant toxicity in the triplet arm due to the addition of palbociclib.

Grade 3 or higher treatment-related adverse events in Study 1

Adverse event	Gedatolisib triplet	Gedatolisib doublet	Fulvestrant
Neutropenia	62.3%	0.8%	0.8%
Stomatitis	19.2%	12.3%	0%
Rash	4.6%	5.4%	0%
Hyperglycemia	2.3%	2.3%	0%
Diarrhea	1.5%	0.8%	0%
Nausea	3.8%	0.8%	0%
Leukopenia (grade 4)	0.8%	0%	0%
Pneumonitis (grade 4)	0%	0.8%	0%
Treatment discontinuation due to TRAEs	2.3%	3.1%	—

Source: Hurvitz SA et al. JCO. 2026. PMC13075786.

Stomatitis: The most characteristic and commonly discussed gedatolisib-specific toxicity. Grade 3 stomatitis occurred in 19.2% (triplet) and 12.3% (doublet) of patients. Importantly, among patients who did develop stomatitis, the majority experienced grade 1 as their first event (57 of 90 in the triplet arm; 48 of 74 in the doublet arm), with fewer progressing to grade 2 or 3 as their initial presentation. Stomatitis is a class effect of PI3K and mTOR inhibitors and is managed with prophylactic mouthwash protocols, dose modifications, and patient education on early symptom reporting. The treatment discontinuation rate due to stomatitis alone was low (overall discontinuation for any TRAE was 2.3% in the triplet and 3.1% in the doublet).

Neutropenia in the triplet: The high grade 3 or higher neutropenia rate of 62.3% in the triplet arm is driven primarily by the palbociclib component, consistent with palbociclib’s established neutropenia profile in all of its approved regimens. CBC monitoring before each cycle and dose modification per the Revtorpyk and palbociclib prescribing information apply. The neutropenia rate in the doublet (0.8%) confirms that gedatolisib itself does not substantially contribute to bone marrow suppression; this is a palbociclib effect in the triplet.

Hyperglycemia: PI3K inhibition affects insulin signaling, and hyperglycemia is a known class effect. Grade 3 hyperglycemia occurred in 2.3% of patients in both gedatolisib arms. Blood glucose monitoring before treatment initiation and periodically during treatment, with dose modification and antidiabetic medication management as appropriate, follows the established management framework for PAM pathway inhibitors. Patients with pre-existing diabetes should be closely monitored.

Pneumonitis: Grade 4 pneumonitis occurred in 0.8% of doublet-treated patients. Pneumonitis is a known and serious risk associated with PI3K and mTOR inhibitors as a class. Patients should be monitored for new or worsening pulmonary symptoms; grade 2 or higher pneumonitis typically requires treatment interruption and corticosteroid management, with permanent discontinuation for grade 3 or higher.

Key warnings and precautions (from Revtorpyk prescribing information):

Warning	Clinical guidance
Hyperglycemia	Fasting glucose before initiating and periodically during treatment; dose modification for grade 3 or higher; may require antidiabetic medication initiation or dose adjustment
Stomatitis	Oral hygiene and prophylactic mouthwash regimens recommended before initiating; dose modification for grade 2 or higher; patient education on early reporting
Pneumonitis	Monitor for pulmonary symptoms; hold for grade 2 pneumonitis; permanently discontinue for grade 3 or higher
Embryo-fetal toxicity	Gedatolisib can cause fetal harm; effective contraception during treatment and for at least the period specified in prescribing information after last dose
Neutropenia (triplet)	CBC at baseline and before each cycle; dose modifications per palbociclib and Revtorpyk prescribing information for grade 3 or higher neutropenia

What This Means in Clinical Practice

For patients with HR+/HER2- PIK3CA wild-type advanced breast cancer

If you have HR-positive, HER2-negative metastatic breast cancer, your tumor has been tested and does not have a PIK3CA mutation, and your disease has progressed on or after prior endocrine therapy (including CDK4/6 inhibitor-based regimens), you are now in the patient population for which Revtorpyk is approved. This is the first targeted agent specifically approved for your PIK3CA status in this disease.

The treatment involves weekly IV infusions (three per four-week cycle) plus fulvestrant injections and, in the triplet, oral palbociclib. The clinical decision between the triplet and doublet depends on your prior therapy, current blood counts, and your oncologist’s assessment of the most appropriate regimen for your situation. Patients who have previously received a CDK4/6 inhibitor may or may not be candidates for the triplet re-challenge with palbociclib depending on the reasons for prior CDK4/6 inhibitor discontinuation.

For oncologists

VIKTORIA-1 Study 1 establishes gedatolisib plus fulvestrant, with or without palbociclib, as a new evidenced-based option for post-CDK4/6 inhibitor PIK3CA wild-type HR+/HER2- advanced breast cancer. The hazard ratios of 0.24 (triplet) and 0.33 (doublet) represent strong clinical benefit signals in a population with historically limited targeted options.

The companion diagnostic testing requirement adds a testing step to the treatment planning workflow that should now be standardized for all HR+/HER2- advanced breast cancer patients progressing on CDK4/6 inhibitor therapy, covering both PIK3CA mutation testing (to identify alpelisib/inavolisib-eligible patients) and confirming wild-type status for gedatolisib eligibility. ESR1 mutation testing for elacestrant eligibility remains a parallel testing requirement that the same blood sample or tissue can typically address.

The weekly infusion schedule is a meaningful practical factor in patient selection and treatment planning. Patients whose performance status, transportation access, and support systems make weekly clinic visits feasible are appropriate candidates; for patients where this frequency is a significant barrier, the clinical conversation should include the doublet, which has the same visit schedule but without the oral palbociclib complexity.

Dr. Joyce O’Shaughnessy of Baylor University Medical Center noted that in her opinion, this could be immediately practice changing, given the PFS data in both the PIK3CA wild-type and PIK3CA-mutant populations being consistently better than the control arm.

The upcoming sNDA for the PIK3CA-mutant indication (planned Q3 2026 submission) is the next major regulatory event to watch. If approved, gedatolisib will cover the full HR+/HER2- post-endocrine therapy population and PIK3CA testing will guide regimen selection and comparator benchmarking rather than drug eligibility.

For related HED coverage on HR+/HER2- breast cancer approvals, see our post on palbociclib (Ibrance) receiving its first HER2-positive breast cancer approval for HR+/HER2+ maintenance and our post on Trodelvy (sacituzumab govitecan) receiving two new first-line approvals for metastatic TNBC.

For patients and families navigating an HR-positive metastatic breast cancer diagnosis, the National Breast Cancer Foundation (nationalbreastcancer.org), the Susan G. Komen Foundation (komen.org; 1-877-GO-KOMEN), and the LBBC (Living Beyond Breast Cancer) maintain current resources on treatment options, clinical trials, and financial assistance.

Sources

FDA approval announcement: FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer. FDA.gov. July 14, 2026.

Celcuity FDA approval press release: Celcuity Announces FDA Approval of REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer. GlobeNewswire. July 14, 2026.

Drugs.com approval news: FDA Approves Revtorpyk (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer. drugs.com. July 14, 2026.

VIKTORIA-1 Study 1 JCO primary publication (March 2026): Hurvitz SA et al. VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor-positive/HER2-/PIK3CA wild-type advanced breast cancer. Journal of Clinical Oncology. 2026. doi:10.1200/JCO-25-02643.

VIKTORIA-1 trial registration: NCT05501886. ClinicalTrials.gov.

Celcuity JCO publication press release (March 9, 2026): Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study. GlobeNewswire. March 9, 2026.

CancerNetwork full efficacy and clinical context (with Dr. O’Shaughnessy quote): FDA Approves Gedatolisib for HR+, HER2- PIK3CA Wild-Type Advanced Breast Cancer. cancernetwork.com. July 2026.

Targeted Oncology (RTOR, Breakthrough Therapy designation, ASCO context): FDA Approves Gedatolisib for HR+/HER2-, PIK3CA Wild-Type Advanced Breast Cancer. targetedonc.com. July 2026.

Pharmacy Times (full safety table, mechanism detail): Gedatolisib Combination Approved for PIK3CA Wild-Type HR+, HER2- Breast Cancer. pharmacytimes.com. July 2026.

CURE (patient-facing dosing and administration detail): FDA Approves Revtorpyk for Advanced HR-Positive, HER2-Negative Breast Cancer. curetoday.com. July 2026.

VIKTORIA-1 ESMO 2025 presentation (Celcuity PDF): VIKTORIA-1 PIK3CA WT ESMO Presentation. celcuity.com. October 2025.

CancerNetwork VIKTORIA-1 Study 2 ASCO 2026 data (mutant cohort): VIKTORIA-1 Regimen Shows Efficacy in PIK3CA+ Breast Cancer. cancernetwork.com. June 2026.

VIKTORIA-1 Study 2 ASCO 2026 abstract: Hurvitz SA et al. VIKTORIA-1 Study 2. J Clin Oncol. 44, 2026 (suppl 17; abstr LBA1008). doi:10.1200/JCO.2026.44.17_suppl.LBA1008.

FCS Hematology Oncology Review (complete grade 3/4 safety table): VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib. fcshemoncreview.com.

PI3K/AKT/mTOR pathway biology: PI3K/AKT/mTOR Signaling in Cancer. PMC7734386.

Breast cancer overview: Breast Cancer. StatPearls. NCBI.

Alpelisib FDA approval (PIK3CA-mutant reference): FDA approves alpelisib for breast cancer. FDA.gov.

Revtorpyk prescribing information: REVTORPYK (gedatolisib) Prescribing Information. Celcuity Inc. 2026.

Revtorpyk approval history: Revtorpyk FDA Approval History. drugs.com.

Patient resources: National Breast Cancer Foundation | Susan G. Komen Foundation: 1-877-GO-KOMEN | Living Beyond Breast Cancer | Celcuity Revtorpyk patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Revtorpyk (gedatolisib) requires PIK3CA wild-type confirmation by an FDA-authorized companion diagnostic assay before initiating treatment. Treatment decisions for HR-positive, HER2-negative advanced breast cancer, including regimen selection following CDK4/6 inhibitor-based therapy, should be made in close collaboration with a board-certified medical oncologist experienced in breast cancer management and familiar with the full clinical context including prior therapy, mutation status, and performance status.

July 17, 2026

Triple-Negative Breast Cancer Has Had No Good First-Line Option for Patients Who Cannot Take Immunotherapy. Trodelvy Just Became the First Advance in 20 Years for That Population and the New Standard for Those Who Can. Here Is What the ASCENT-03 and ASCENT-04 Data Shows.

The essentials: On June 24, 2026, the FDA approved two new first-line indications for Trodelvy (sacituzumab govitecan-hziy, Gilead Sciences) in adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): Indication 1 (monotherapy): as a single agent for adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. Supported by ASCENT-03. Indication 2 (combination): in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (combined positive score [CPS] at or above 10) as determined by an FDA-authorized test. Supported by ASCENT-04/KEYNOTE-D19. These are new first-line approvals; Trodelvy was previously approved for second-line and later treatment in TNBC (2020) and HR+/HER2-low breast cancer (2023). The clinical basis: ASCENT-03 (NCT05382299): 558 patients, first-line TNBC ineligible for PD-(L)1 inhibitors, randomized 1:1 to sacituzumab govitecan 10 mg/kg days 1 and 8 of a 21-day cycle versus physician’s choice chemotherapy. Median PFS 9.7 months versus 6.9 months; HR 0.62 (95% CI 0.50 to 0.77; p less than 0.0001); 38% reduction in risk of progression or death. Median DOR 12.2 months versus 7.2 months. ORR 48% versus 46%. OS data immature. ASCENT-04/KEYNOTE-D19 (NCT05382286): 443 patients, first-line PD-L1-positive (CPS at or above 10) TNBC, randomized to sacituzumab govitecan plus pembrolizumab versus physician’s choice chemotherapy plus pembrolizumab. Median PFS 11.2 months versus 7.8 months; HR 0.65 (95% CI 0.51 to 0.84; p=0.0009); 35% reduction in risk of progression or death. Confirmed ORR 61% versus 55%. OS not reached in either arm at data cutoff. Mechanism: sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate (ADC) that delivers the topoisomerase I inhibitor SN-38 specifically to Trop-2-expressing cancer cells. Trop-2 is highly expressed in TNBC. Boxed warnings: severe neutropenia; severe diarrhea. Both are manageable with established protocols.

Triple-negative breast cancer is defined by what it lacks: no estrogen receptor expression, no progesterone receptor expression, and no HER2 overexpression. That combination of absences eliminates three of the most productive therapeutic targets in modern breast cancer medicine. There is no endocrine therapy. There is no HER2-directed antibody. For decades, the treatment toolkit for TNBC was essentially the same chemotherapy regimens that oncology had in the 1990s.

The arrival of pembrolizumab plus chemotherapy for PD-L1-positive TNBC in 2021 represented the last major first-line shift. But pembrolizumab only helps patients whose tumors express PD-L1 at adequate levels, roughly half of the metastatic TNBC population. For the other half, the patients with PD-L1-negative disease or contraindications to immunotherapy, the standard of care in 2025 was still first-line chemotherapy.

That remained true for more than 20 years after TNBC was first defined as a distinct subtype. As Dr. Javier Cortés, Head of the International Breast Cancer Center in Spain and principal investigator of ASCENT-03, put it: the ASCENT-03 outcome represents the first clinically meaningful advance for this patient population in more than 20 years.

The June 24, 2026 FDA approvals give Trodelvy (sacituzumab govitecan-hziy, Gilead Sciences) a first-line role across the full spectrum of metastatic TNBC, whether or not the patient is eligible for immunotherapy, based on two Phase 3 trials both published in the New England Journal of Medicine.

What Triple-Negative Breast Cancer Is and Why It Has Been So Hard to Treat

Breast cancer is not one disease. It is a collection of molecularly distinct subtypes with different drivers, different natural histories, and different therapeutic vulnerabilities. The most common subtypes, hormone receptor-positive breast cancers, are driven by estrogen and progesterone signaling and are treated with endocrine therapies that can maintain disease control for years. HER2-positive cancers are driven by HER2 amplification and are effectively treated with targeted antibodies and antibody-drug conjugates. Both subtypes have seen dramatic survival improvements over the past 30 years.

Triple-negative breast cancer accounts for approximately 10 to 15% of all breast cancers, but its clinical impact is disproportionate to its prevalence. TNBC is more common in younger women and is overrepresented in women of African descent, for whom the incidence rate is approximately double that of white women. It tends to grow rapidly and metastasize early. Unlike hormone receptor-positive disease, which can smolder for years before progressing, TNBC often spreads and becomes lethal within months of metastatic diagnosis.

The five-year survival rate for metastatic TNBC is approximately 12%, compared with 28% for other metastatic breast cancer subtypes. Nearly half of patients diagnosed with metastatic TNBC never receive a second line of therapy, making the first line of treatment the most consequential decision in their care. That clinical reality is the context within which both ASCENT-03 and ASCENT-04 must be understood.

The PD-L1 split that defines the treatment landscape

The 2021 approval of pembrolizumab plus chemotherapy (KEYNOTE-522) for PD-L1-positive metastatic TNBC was a meaningful advance, but it created a fork in the treatment pathway. To receive pembrolizumab, patients must have PD-L1 expression with a combined positive score (CPS) at or above 10, as measured by the PD-L1 IHC 22C3 pharmDx assay. Patients who are PD-L1-negative by this criterion, or who have contraindications to checkpoint inhibition (autoimmune conditions, organ transplantation, severe prior immune-related adverse events), have not been eligible for the pembrolizumab combination and have faced first-line chemotherapy alone.

ASCENT-03 is specifically designed for this PD-L1-ineligible population. ASCENT-04 targets the PD-L1-positive population and asks whether replacing chemotherapy with an ADC as the partner to pembrolizumab improves on the current standard.

The Science: What Sacituzumab Govitecan Is and How It Works

Sacituzumab govitecan is an antibody-drug conjugate (ADC): a targeted delivery vehicle that combines a cancer-specific antibody with a cytotoxic drug payload, connected by a chemical linker designed to release the payload preferentially inside tumor cells.

The three components of sacituzumab govitecan are:

The antibody: anti-Trop-2. Trop-2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is highly expressed on the surface of many epithelial cancer cells, including the vast majority of TNBC tumors. Its expression in normal adult tissues is comparatively low, making it a useful tumor-targeting antigen. The anti-Trop-2 antibody in sacituzumab govitecan binds to Trop-2-expressing cancer cells and is internalized through receptor-mediated endocytosis, bringing the payload inside the cell.

The linker: hydrolysable. Unlike ADCs with stable, non-cleavable linkers that only release payload inside target cells, the hydrolysable linker in sacituzumab govitecan releases some active payload in the tumor microenvironment after internalization. This creates a “bystander effect”: neighboring cancer cells that may express lower levels of Trop-2 are also exposed to SN-38, potentially expanding the drug’s activity beyond the highest-Trop-2-expressing cells.

The payload: SN-38. SN-38 is the active metabolite of irinotecan, a topoisomerase I inhibitor. Topoisomerase I is an enzyme that relieves torsional stress in DNA during replication by creating temporary single-strand breaks. SN-38 traps topoisomerase I in a complex with DNA, preventing the breaks from being resealed. The result is irreversible DNA double-strand breaks during replication, triggering apoptosis. SN-38 is approximately 100 to 1,000 times more potent than irinotecan itself. The ADC delivery format allows higher intratumoral concentrations of SN-38 than would be tolerable with systemic irinotecan.

The drug-to-antibody ratio (DAR) of sacituzumab govitecan is approximately 7.6, meaning roughly 7 to 8 SN-38 molecules are attached per antibody. This high DAR, unusual among approved ADCs, contributes to the drug’s potency at Trop-2-expressing tumors.

ASCENT-03: The Monotherapy Indication

Design

ASCENT-03 (NCT05382299) was a Phase 3, multicenter, open-label, randomized trial enrolling 558 adults with unresectable locally advanced or metastatic TNBC who had not received prior systemic therapy for advanced disease and who were not candidates for PD-1 or PD-L1 inhibitor therapy. The enrollment criteria specifically required that patients either had PD-L1-negative tumors (CPS below 10) or had PD-L1-positive tumors but could not receive immunotherapy due to comorbidities.

Patients were randomized 1:1 to:

Sacituzumab govitecan 10 mg/kg IV on days 1 and 8 of a 21-day cycle
Physician’s choice chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin)

The primary endpoint was progression-free survival (PFS) per blinded independent central review (BICR). Key secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DOR), and safety.

Results

At a median follow-up of 13.2 months, sacituzumab govitecan demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy, with a median PFS of 9.7 months versus 6.9 months, representing a 38% reduction in the risk of disease progression or death (HR 0.62; 95% CI 0.50 to 0.78; p less than 0.0001). BioSpace

Endpoint	Sacituzumab govitecan	Chemotherapy (TPC)	Result
Median PFS (BICR)	9.7 months (95% CI 8.1 to 11.1)	6.9 months (95% CI 5.6 to 8.2)	HR 0.62 (95% CI 0.50 to 0.77); p less than 0.0001
Risk reduction in progression or death	38%	Reference	—
ORR	48% (95% CI 42% to 54%)	46% (95% CI 40% to 52%)	Comparable
Median DOR	12.2 months (95% CI 9.7 to 13.8)	7.2 months (95% CI 5.7 to 8.4)	Substantially longer with SG
Median PFS2 (time to next progression)	18.2 months (95% CI 15.9 to NR)	14.0 months (95% CI 12.5 to 17.4)	HR 0.70 (95% CI 0.55 to 0.90)
OS	Data immature (37% maturity at cutoff)	Data immature	No OS detriment observed

Source: Cortés J et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. NEJM. 2025. doi:10.1056/NEJMoa2511734. ASCENT-03, abstract LBA20, ESMO 2025.

The ORR was 48% with sacituzumab govitecan versus 46% with chemotherapy, with similar rates but a substantially longer median DOR with sacituzumab govitecan (12.2 months versus 7.2 months). The PFS benefit was consistent across prespecified subgroups, including patients with poor prognostic features such as disease recurrence within one year of prior curative therapy. FDA

The treatment discontinuation rate due to adverse events was lower with sacituzumab govitecan than with chemotherapy, a finding that supports the tolerability of the ADC relative to standard cytotoxic regimens in this population.

ASCENT-04/KEYNOTE-D19: The Combination Indication

Design

ASCENT-04/KEYNOTE-D19 (NCT05382286) was a Phase 3, multicenter, open-label, randomized trial enrolling 443 adults with locally advanced or metastatic TNBC who had not received prior systemic therapy for advanced disease and whose tumors expressed PD-L1 at a CPS of 10 or greater, confirmed centrally using the PD-L1 IHC 22C3 pharmDx assay.

Patients were randomized to:

Sacituzumab govitecan 10 mg/kg IV days 1 and 8 of a 21-day cycle plus pembrolizumab 200 mg IV on day 1 every 3 weeks (n=221)
Physician’s choice chemotherapy plus pembrolizumab 200 mg IV on day 1 every 3 weeks (n=222)

The primary endpoint was PFS by BICR.

Results

At a data cutoff of March 3, 2025, sacituzumab govitecan plus pembrolizumab led to a median PFS of 11.2 months (95% CI 9.3 to 16.7) versus 7.8 months (95% CI 7.3 to 9.3) with chemotherapy plus pembrolizumab, translating to a 35% reduction in the risk of disease progression or death (HR 0.65; 95% CI 0.51 to 0.84; p less than 0.001). Patient Care Online

Endpoint	SG plus pembrolizumab	Chemo plus pembrolizumab	Result
Median PFS (BICR)	11.2 months (95% CI 9.3 to 16.7)	7.8 months (95% CI 7.3 to 9.3)	HR 0.65 (95% CI 0.51 to 0.84); p=0.0009
Risk reduction in progression or death	35%	Reference	—
6-month PFS rate	72% (95% CI 65% to 77%)	63% (95% CI 56% to 70%)	—
12-month PFS rate	48% (95% CI 41% to 56%)	38% (95% CI 31% to 45%)	—
Confirmed ORR	61% (95% CI 55% to 68%)	55% (95% CI 48% to 62%)	—
Median OS	Not reached	Not reached	Immature; no OS detriment

Source: Tolaney SM et al. Sacituzumab govitecan plus pembrolizumab in first-line PD-L1-positive TNBC. ASCO 2025 / NEJM 2025. doi:10.1056/NEJMoa2511736. ASCENT-04/KEYNOTE-D19 NCT05382286.

An important contextual note: 43% of patients on the chemotherapy-plus-pembrolizumab arm crossed over to receive sacituzumab govitecan as a single agent in the second line, accounting for 81% of those who received subsequent treatment. The fact that the combination still showed statistically significant PFS benefit despite high crossover to the ADC in the control arm’s next line is a meaningful finding, because crossover typically dilutes the OS benefit in second-line crossover-heavy trials. Patient Care Online

Dr. Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and principal investigator for ASCENT-04, described the combination as resulting in a statistically significant and clinically meaningful improvement in PFS in the first-line PD-L1-positive metastatic TNBC setting.

The Approval Framework: Two Indications Split by PD-L1 Status

The two new approvals create a rational treatment framework that mirrors how oncologists already stratify TNBC patients before initiating first-line therapy:

Patient profile	New first-line standard of care	Trial support
TNBC, not eligible for PD-(L)1 inhibitor therapy (PD-L1 CPS below 10, or contraindicated)	Trodelvy monotherapy (sacituzumab govitecan)	ASCENT-03
TNBC, PD-L1 CPS at or above 10 (confirmed by FDA-authorized assay)	Trodelvy plus Keytruda or Keytruda Qlex (sacituzumab govitecan plus pembrolizumab)	ASCENT-04

The key practical implication for oncology teams: PD-L1 testing using the 22C3 pharmDx assay is now a required step in first-line treatment planning for metastatic TNBC. This test was already standard of care at many centers for the pembrolizumab decision; the new approvals make it universal.

Ricki Fairley, co-founder and CEO of TOUCH, The Black Breast Cancer Alliance, noted that because so many patients may never receive subsequent lines of therapy, the ability to start with an effective option like Trodelvy with or without Keytruda in the first line is critical, particularly given TNBC’s disproportionate impact on Black women.

Trodelvy’s Complete Indication Picture After June 2026

Trodelvy now holds approvals across multiple settings in TNBC and beyond: Contagion Live

Indication	Approval date	Key trial
Previously treated (at or above 2 prior lines) metastatic TNBC	April 2020	ASCENT
Previously treated unresectable locally advanced or metastatic HR+/HER2-low breast cancer after endocrine therapy	February 2023	TROPiCS-02
First-line metastatic TNBC, not eligible for PD-(L)1 inhibitors (monotherapy)	June 24, 2026	ASCENT-03
First-line metastatic TNBC, PD-L1 CPS at or above 10 (plus pembrolizumab)	June 24, 2026	ASCENT-04

Safety: What Prescribers and Patients Need to Know

Sacituzumab govitecan carries a boxed warning for two serious adverse reactions, both attributable to the SN-38 topoisomerase I inhibitor payload.

Severe neutropenia (boxed warning): Grade 3 or higher neutropenia occurred in 43% of sacituzumab govitecan-treated patients in ASCENT-03. Neutropenia is the most clinically significant toxicity and requires proactive management. Granulocyte colony-stimulating factor (G-CSF) prophylaxis is strongly recommended and substantially reduces the severity and duration of neutropenic episodes. Complete blood count monitoring before each dose is standard. Dose reduction or delay may be required for severe neutropenia. Sanofi

Severe diarrhea (boxed warning): SN-38 causes significant gastrointestinal toxicity through its topoisomerase I inhibition in intestinal epithelium. Grade 3 or higher diarrhea occurred in 9% of sacituzumab govitecan-treated patients in ASCENT-03, compared with 16% with anemia in the chemotherapy arm. Management includes early loperamide at the first sign of loose stools and dose modification for persistent severe diarrhea. Patients with UGT1A1*28 homozygous genotype (reduced SN-38 glucuronidation) are at higher risk for both neutropenia and diarrhea and require dose reduction. Sanofi

Additional key safety information:

Safety item	Details	Clinical guidance
Severe neutropenia (boxed warning)	Grade 3 or higher neutropenia in approximately 43% in ASCENT-03; febrile neutropenia possible	G-CSF prophylaxis strongly recommended; CBC before each dose; dose modification per prescribing information
Severe diarrhea (boxed warning)	Grade 3 or higher in approximately 9%; early-onset (within days of infusion) common	Loperamide at first sign of loose stools; dose modification for severe or persistent diarrhea
UGT1A1 genotype	Patients homozygous for UGT1A128 (poor metabolizers) have reduced SN-38 clearance and higher toxicity risk	Starting dose reduction to 7.5 mg/kg recommended in homozygous UGT1A128 patients
Nausea and vomiting	Common; manageable with antiemetics	Prophylactic antiemetics recommended; anti-nausea medications as needed
Hypersensitivity and infusion reactions	Severe reactions including anaphylaxis reported	Premedication; monitoring during infusion; resuscitation capability required
Embryo-fetal toxicity	SN-38 can cause fetal harm	Effective contraception during treatment and for 6 months after last dose for females; 3 months for males
Pembrolizumab-related toxicities (combination indication)	Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies; infusion reactions	Refer to Keytruda prescribing information for full immune-related AE management guidance
Serious adverse reactions in ASCENT-03 CheckRare	Occurred in 26% of patients; fatal adverse reactions in 2.5%	Close clinical monitoring; dose modification per prescribing information

What This Means for Patients and Oncology Teams

For patients with metastatic TNBC not eligible for immunotherapy

This population has had no meaningful treatment advance since TNBC was defined more than 20 years ago. ASCENT-03 represents the first clinically meaningful advance for this patient population in over 20 years, according to Dr. Cortés. The 38% reduction in progression risk, the nearly 3-month improvement in median PFS (9.7 versus 6.9 months), and the dramatically longer duration of response (12.2 versus 7.2 months) constitute a clinically significant departure from what chemotherapy alone has provided. Pfizer

For oncologists managing these patients: sacituzumab govitecan monotherapy is now an FDA-approved first-line standard for PD-(L)1-ineligible metastatic TNBC. The G-CSF prophylaxis requirement and the UGT1A1 genotype assessment should be part of the treatment initiation workup.

For patients with PD-L1-positive metastatic TNBC

The ASCENT-04 data establishes sacituzumab govitecan plus pembrolizumab as a new first-line option for patients with CPS at or above 10, with a 35% reduction in progression risk over the prior standard of chemotherapy plus pembrolizumab. The combination’s 11.2-month median PFS and 61% ORR represent a meaningful improvement over what was achievable in this setting.

The combination requires PD-L1 testing before initiation, coordination of the ADC and checkpoint inhibitor schedules, and management of both SN-38 toxicities (neutropenia, diarrhea) and potential immune-mediated adverse events from pembrolizumab.

The sequencing question and OS data

One important clinical caveat applies to both approvals: overall survival data were immature at the time of analysis for both ASCENT-03 and ASCENT-04. The PFS benefit is established and statistically significant, but whether first-line Trodelvy translates into longer overall survival will depend on mature OS data from ongoing follow-up. Given the high crossover rate in ASCENT-04 (43% of control arm patients received sacituzumab govitecan in the second line), the OS signal may be attenuated even if the drug provides genuine survival benefit. These are data to watch in updated analyses from both trials.

For patients and families navigating a new metastatic TNBC diagnosis: the National Breast Cancer Foundation, Susan G. Komen Foundation, and TOUCH, The Black Breast Cancer Alliance all maintain current patient resources including clinical trial locators and financial assistance navigation for Trodelvy access.

For related HED coverage on oncology ADC approvals and breast cancer treatment advances, see our prior coverage on Pomalyst (pomalidomide) and what the multiple myeloma treatment landscape looks like as generic competition arrives in the 2026 LOE series.

Sources

FDA approval announcement: FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. FDA.gov. June 24, 2026.

Gilead press release: U.S. FDA approves Trodelvy for first-line treatment of metastatic triple-negative breast cancer. gilead.com. June 24, 2026.

ASCO Post approval summary: FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC. ascopost.com. June 2026.

Pharmacy Times clinical review: FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer. pharmacytimes.com. June 2026.

BioPharm International clinical summary: Trop-2-Directed ADC Sacituzumab Govitecan Earns FDA Approval in First-Line Metastatic TNBC. biopharminternational.com. June 2026.

CancerNetwork detailed clinical summary: Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications. cancernetwork.com. June 2026.

OncLive: ASCENT-04 primary analysis and Dr. Tolaney commentary: Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC. onclive.com. June 2026.

ASCENT-03 primary NEJM publication: Cortés J et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2511734.

ASCENT-03 ESMO 2025 abstract (LBA20): Cortés JC et al. Primary results from ASCENT-03. Presented at ESMO Congress 2025. October 19, 2025. Berlin, Germany.

ASCENT-03 trial registration: NCT05382299. ClinicalTrials.gov.

ASCENT-04 primary NEJM publication: Tolaney SM et al. Sacituzumab govitecan plus pembrolizumab in first-line PD-L1-positive TNBC. NEJM. 2025. doi:10.1056/NEJMoa2511736.

ASCENT-04 trial registration: NCT05382286. ClinicalTrials.gov.

ASCENT-04 PFS2 and subsequent therapy data: Kalinsky K et al. PFS2 and subsequent therapies in ASCENT-04. ASCO 2026.

ADC mechanism and Trop-2 biology: Antibody-Drug Conjugates in Cancer Therapy. PMC7734386.

Sacituzumab govitecan StatPearls: Sacituzumab Govitecan. StatPearls. NCBI.

TNBC overview: Triple-Negative Breast Cancer. StatPearls. NCBI.

Pembrolizumab plus chemo TNBC approval (KEYNOTE-522): FDA approves pembrolizumab for triple-negative breast cancer. FDA.gov.

ACS TNBC overview: Triple-Negative Breast Cancer. cancer.org.

Patient resources: National Breast Cancer Foundation | Susan G. Komen Foundation | TOUCH, The Black Breast Cancer Alliance | Gilead Trodelvy patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Trodelvy (sacituzumab govitecan-hziy) carries a boxed warning for severe neutropenia and severe diarrhea. Treatment decisions for metastatic TNBC, including the choice between monotherapy and combination regimens and the role of PD-L1 testing in treatment planning, should be made in close collaboration with a board-certified medical oncologist experienced in breast cancer management.

June 30, 2026

Datroway Is Now FDA-Approved for Immunotherapy-Ineligible Metastatic TNBC. Here Is What the TROPION-Breast02 Data Shows and What the Accelerated Approval Means.

Updated May 26, 2026: FDA Approval Confirmed On May 22, 2026, the FDA approved Datroway (datopotamab deruxtecan-dlnk, AstraZeneca/Daiichi Sankyo) for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. This is the first TROP2-directed ADC approved in this setting and the first targeted therapy to demonstrate a statistically significant overall survival advantage over chemotherapy in first-line immunotherapy-ineligible metastatic TNBC. Important regulatory note: this indication was approved under accelerated approval based on objective response rate (63% vs. 29%) and duration of response (12.3 vs. 7.1 months) as the regulatory basis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. The PFS and OS data from TROPION-Breast02 (detailed below) provide the broader efficacy context but are not the formal basis of this particular approval. NCCN update: Following the approval, Datroway was added to the NCCN Clinical Practice Guidelines as a Category 1 preferred first-line treatment option for metastatic TNBC patients who are not candidates for immunotherapy. Global status: As of May 22, 2026, regulatory reviews are ongoing in the EU, China, Japan, Australia, Canada, Singapore, and Switzerland. Datroway’s full approved indication list now includes: HR-positive, HER2-negative metastatic breast cancer (approved January 2025); EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum chemotherapy (accelerated approval); and metastatic TNBC ineligible for PD-1/PD-L1 inhibitor therapy (approved May 22, 2026, accelerated approval).

Triple-negative breast cancer is defined by what it lacks: no estrogen receptor, no progesterone receptor, no HER2 amplification. Those absences mean that the targeted therapies which have transformed outcomes in other breast cancer subtypes do not apply here. For decades, chemotherapy was the only systemic option. Then, in 2020, immunotherapy arrived for patients whose tumors expressed the PD-L1 protein. A meaningful advance for those patients. But not everyone qualifies.

Patients with metastatic TNBC who are ineligible for immunotherapy have historically had the fewest options and the worst outcomes of any breast cancer population. Their first-line treatment has remained standard cytotoxic chemotherapy, with all the toxicity that entails and a median overall survival below two years.

Datopotamab deruxtecan (Dato-DXd, brand name Datroway) is now seeking to change that. Developed by AstraZeneca and Daiichi Sankyo, the drug already received FDA approval in January 2025 for a different breast cancer subtype (HR-positive, HER2-negative). Now it has Priority Review for a new indication: first-line treatment of metastatic TNBC in patients who are not candidates for immunotherapy. The PDUFA date falls in Q2 2026. The Phase 3 TROPION-Breast02 trial, published in the Annals of Oncology in April 2026, produced results that oncologists are calling a potential new standard of care.

Triple-Negative Breast Cancer: The Biology, the Burden, and the Disparities

Triple-negative breast cancer accounts for approximately 15% of all breast cancer diagnoses in the United States, roughly 35,000 new cases per year. Despite representing a minority of breast cancer cases, it accounts for a disproportionate share of breast cancer deaths because of its aggressive biology, its relative resistance to treatment, and its tendency to be diagnosed at younger ages and at more advanced stages.

The racial disparities in TNBC are well documented and clinically significant. Black women are diagnosed with TNBC at roughly twice the rate of white women. They are more likely to be diagnosed at younger ages and more advanced stages. And despite these higher incidence rates, access to specialist oncology care and novel therapies has historically been unequal. Any advance in TNBC outcomes is therefore not just an oncologic milestone but a health equity issue.

Who is ineligible for immunotherapy in TNBC, and why this population matters Since 2020 and 2021, PD-L1 checkpoint inhibitors (atezolizumab and then pembrolizumab) have been approved as first-line options for metastatic TNBC. Pembrolizumab with chemotherapy is now the standard of care for PD-L1-positive metastatic TNBC, and it produces a meaningful survival benefit in that population. However, PD-L1 positivity is not universal in TNBC. Depending on the assay and scoring method used, approximately 40 to 60 percent of metastatic TNBC patients have PD-L1-positive tumors. The remainder, along with patients who cannot receive immunotherapy due to autoimmune disease, organ transplant status, or other contraindications, fall into the immunotherapy-ineligible category. TROPION-Breast02 enrolled specifically and exclusively these patients. This is the population for which first-line treatment has remained unchanged at standard chemotherapy for decades, and the population for which Dato-DXd is seeking approval.

What Is Dato-DXd and How Does It Work?

Datopotamab deruxtecan is an antibody-drug conjugate, part of the same drug class as trastuzumab deruxtecan (Enhertu/T-DXd) and sacituzumab govitecan (Trodelvy). All ADCs share the same general architecture: an antibody that recognizes a target protein on cancer cell surfaces, linked to a chemotherapy payload. The antibody finds the cancer cell, binds to it, is internalized, and releases the payload inside the cell.

Dato-DXd’s target is TROP2 (trophoblast cell-surface antigen 2), a protein expressed at high levels on the surface of many solid tumors, including the majority of TNBC tumors. The payload is DXd, a topoisomerase I inhibitor derived from exatecan. When the ADC is internalized into TROP2-expressing tumor cells, the linker is cleaved and DXd is released inside the cell, interfering with DNA replication and causing cancer cell death.

The linker technology is an important distinguishing feature. The cleavable tetrapeptide-based linker used in Dato-DXd is designed to be stable in the bloodstream but cleaved efficiently inside cells. This stability reduces off-target payload release in circulation, which contributes to a lower rate of hematologic toxicity compared to some earlier ADC platforms. The same DXd payload and linker technology is used in T-DXd (Enhertu), which explains the shared class safety signal of interstitial lung disease and stomatitis across both drugs.

Dato-DXd versus sacituzumab govitecan (Trodelvy): both target TROP2, but differently Sacituzumab govitecan (Trodelvy) is the other FDA-approved TROP2-directed ADC in breast cancer. It is approved for previously treated metastatic TNBC and for HR-positive HER2-negative metastatic breast cancer. Both it and Dato-DXd target TROP2, but they use different antibodies, different payloads (SN-38 for sacituzumab vs. DXd for datopotamab), and different linker technologies. The practical difference shows up in the safety profile: sacituzumab govitecan has higher rates of hematologic toxicity (neutropenia, diarrhea) while Dato-DXd’s signature toxicities are stomatitis and ocular surface events. Neither has been compared head-to-head in TNBC. They occupy different approved settings, and the question of how to sequence them in the metastatic TNBC treatment landscape is one the field will need to work out as approvals evolve. The panel discussion at OncLive noted that differences in linker technology and payload between the two drugs may influence clinical outcomes, but no definitive comparative data exists. Clinicians should be familiar with both safety profiles to counsel patients appropriately.

TROPION-Breast02: Design and Full Results

Trial design

TROPION-Breast02 (NCT05374512) was a randomized, open-label, international Phase 3 trial conducted across multiple countries. Between May 2022 and June 2024, 644 patients with previously untreated, locally recurrent inoperable or metastatic TNBC who were not candidates for PD-1/PD-L1 inhibitors were randomized 1:1 to Dato-DXd (6 mg/kg intravenously every 3 weeks, n=323) or investigator’s choice of chemotherapy (ICC, n=321). ICC options included paclitaxel, nab-paclitaxel, carboplatin, capecitabine, or eribulin mesylate. Randomization was stratified by geographic region, disease-free interval, and PD-L1 status.

The trial had dual primary endpoints: progression-free survival by blinded independent central review (BICR) per RECIST 1.1, and overall survival. Both primary endpoints were required to demonstrate statistical significance for the trial to be considered successful. Achieving both is a notable distinction in a disease setting where OS data is often immature at the time of initial analysis.

Efficacy results

Efficacy endpoint	Dato-DXd (n=323)	Chemotherapy (n=321)
Median PFS (BICR)	10.8 months (95% CI 8.6–13.0)	5.6 months (95% CI 5.0–7.0)
PFS hazard ratio	0.57 (95% CI 0.47–0.69; p<0.0001)	Reference
Risk reduction in progression/death	43%	Reference
12-month PFS rate	45.6%	25.6%
18-month PFS rate	32.7%	16.8%
Median OS	23.7 months	18.7 months
OS hazard ratio	0.79 (21% reduction in risk of death; p<0.05)	Reference
Median treatment duration	6.7 months	4.1 months
Patients on treatment at data cutoff	Longer than chemo arm	Shorter duration

Source: Dent RA et al. Annals of Oncology. 2026 Apr 3. doi:10.1016/j.annonc.2026.03.008. Presented at ESMO Congress 2025, Berlin (Abstract LBA21).

The PFS result is the most striking number: 10.8 versus 5.6 months is a near doubling of the time to disease progression or death. The 12-month PFS rates tell a related story: at one year, 45.6% of patients on Dato-DXd were progression-free, compared to 25.6% on chemotherapy. At 18 months, those rates were 32.7% versus 16.8%.

The OS result of 23.7 versus 18.7 months represents approximately five additional months of survival, with a statistically significant hazard ratio of 0.79. Having both PFS and OS meet statistical significance in the same trial is an important finding. Many oncology trials achieve PFS endpoints but fail to translate that into an OS benefit, sometimes because subsequent therapies after disease progression equalize outcomes across arms. TROPION-Breast02 demonstrated both.

The 6.7 versus 4.1 month median treatment duration favoring Dato-DXd is an indirect measure of tolerability: patients stayed on the experimental treatment longer, suggesting the drug was manageable enough to continue. That observation is supported by the safety data.

For patients with ER-positive disease, a separate PROTAC-based therapy is simultaneously under FDA review. Read about it here.

Safety: A Different Toxicity Profile Than Chemotherapy

Dato-DXd does not look like chemotherapy in its safety profile. Where chemotherapy predominantly causes hematologic toxicity (neutropenia, anemia, febrile neutropenia), Dato-DXd’s characteristic adverse effects are mucosal (stomatitis) and ocular. This difference matters for patient counseling and clinical management.

Safety metric	Dato-DXd	Chemotherapy (ICC)
Any treatment-related adverse event	93%	83%
Grade 3 or higher TRAEs	33%	29%
Serious treatment-related AEs	9%	8%
Discontinuation due to TRAEs	4%	7%
Treatment-related deaths	0	0
Stomatitis (all grade)	57%	Lower
Nausea (all grade)	45%	Lower
Alopecia (all grade)	41%	21%
Ocular surface events (grade 1, dry eye/keratitis)	24%	3%
ILD/pneumonitis (drug-related, adjudicated)	Less than 1%	Less than 1%
Hematologic toxicity (neutropenia, anemia)	Lower than chemo arm	Predominant toxicity

Several aspects of this safety data are worth emphasizing for clinical context. First, discontinuation due to treatment-related adverse events was actually lower with Dato-DXd (4%) than with chemotherapy (7%). This means patients on the experimental arm were less likely to stop treatment because of toxicity despite the higher overall rate of any adverse event. The profile is different, not simply worse.

Second, stomatitis at 57% is high in absolute terms but predominantly low-grade. The OncLive panel reviewing these results noted that proactive oral care management, including steroid-based mouthwash protocols (expanded from the SWISH trial experience with everolimus), can substantially reduce the incidence and severity of high-grade stomatitis. Institutions implementing Dato-DXd will need nursing education focused on stomatitis prevention and grading.

Third, ocular surface events (dry eye, keratitis) at 24% are almost entirely grade 1 and manageable with lubricating eye drops and ophthalmologic monitoring. The ILD rate of less than 1% is consistent with the known Dato-DXd class signal, lower than what is seen with T-DXd at current doses. ILD monitoring, prompt evaluation of respiratory symptoms, and early intervention with corticosteroids for confirmed cases remain important clinical requirements.

Context: How This Fits Into the TNBC Treatment Landscape

If approved, Dato-DXd would become the first non-chemotherapy, non-immunotherapy first-line option for metastatic TNBC patients who cannot receive checkpoint inhibitors. The treatment landscape for this population would shift in two meaningful ways.

First, the starting line for subsequent treatment sequencing changes. Patients who progress on first-line Dato-DXd will have had an ADC with a specific toxicity profile and resistance pattern. How sacituzumab govitecan (Trodelvy), currently approved in previously treated metastatic TNBC, performs after Dato-DXd progression is not established. This sequencing question will drive post-approval research.

Second, the ADC revolution in breast cancer treatment is now reaching the TNBC immunotherapy-ineligible population specifically. T-DXd reshaped HER2-positive and HER2-low metastatic breast cancer. Sacituzumab govitecan improved outcomes in previously treated TNBC. Dato-DXd, if approved, would extend ADC-based first-line treatment into a subgroup previously limited to cytotoxic chemotherapy.

What the TROPION-Breast01 trial (HR+/HER2- breast cancer) can teach us here Dato-DXd’s January 2025 FDA approval for HR-positive, HER2-negative metastatic breast cancer came from the TROPION-Breast01 trial. That trial met its primary PFS endpoint but did not achieve statistical significance on OS. The explanation offered by investigators was that subsequent ADC treatment in the control arm after disease progression may have equalized survival outcomes. TROPION-Breast02 in TNBC is different in a clinically important way: it achieved statistical significance on both PFS and OS. This distinction matters for the regulatory submission and for clinician confidence. When a trial achieves the survival endpoint and not just the surrogate, the benefit-risk assessment is on firmer ground. The difference in OS outcomes between the two trials also highlights how patient population and available subsequent therapies shape survival data. TNBC patients in TROPION-Breast02 had fewer subsequent treatment options after progression compared to HR+ patients, which may have allowed the OS benefit to emerge more clearly in this trial.

What to Discuss With Your Oncologist Now

What This Approval Means for Patients With Immunotherapy-Ineligible Metastatic TNBC

Datroway is now FDA-approved and available for this population

Datroway (datopotamab deruxtecan-dlnk) is now an FDA-approved first-line option for adults with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. It is the first and only targeted therapy approved in this setting and the first to demonstrate a statistically significant OS advantage over chemotherapy in this population.

NCCN guidelines have been updated following the approval: Datroway is now listed as a Category 1 preferred first-line treatment option for immunotherapy-ineligible metastatic TNBC. Oncologists at NCCN member institutions will begin prescribing based on this recommendation immediately.

Understanding the accelerated approval pathway

The FDA approved the TNBC indication under accelerated approval, using objective response rate (ORR) and duration of response as the regulatory endpoints. The ORR with Datroway was 63% versus 29% with chemotherapy, and median duration of response was 12.3 versus 7.1 months. These are the formal bases for the approval.

This is important context for patients and clinicians. Accelerated approval means the FDA determined that the ORR and duration of response data were sufficiently compelling to authorize use now, while a confirmatory trial verifies long-term clinical benefit. The PFS (10.8 vs. 5.6 months) and OS (23.7 vs. 18.7 months) data from TROPION-Breast02 strongly support the treatment’s value but are not the formal regulatory basis for this approval.

Continued approval may be contingent upon the outcome of the confirmatory trial. This does not mean the drug will be removed from the market; it means AstraZeneca and Daiichi Sankyo must verify the clinical benefit findings as the follow-up matures.

What to discuss with your oncologist now

Has your tumor been tested for PD-L1 expression? If your tumor is PD-L1 positive and you have no contraindications to immunotherapy, pembrolizumab plus chemotherapy remains the approved standard of care.
If you are not a PD-1/PD-L1 candidate, Datroway is now an FDA-authorized first-line option you can discuss with your oncologist as an alternative to standard cytotoxic chemotherapy.
Ask about stomatitis prevention protocols and ocular monitoring, which are the key toxicity management considerations with Datroway.
Ask whether your oncology center has experience with Datroway from the TROPION-Breast02 trial enrollment or from the HR+/HER2- TNBC approval earlier in 2025.
If you are enrolled in or considering a clinical trial involving Datroway, discuss how this approval affects your options with your treating oncologist.

Global availability

For patients outside the United States: Datroway has not yet been approved by the EMA, Health Canada, PMDA (Japan), or TGA (Australia) for the TNBC indication. Regulatory submissions are under review in multiple markets. Check the most current status with your oncologist or the national regulatory authority in your country.

For patients and families navigating a TNBC diagnosis, the Triple Negative Breast Cancer Foundation, Susan G. Komen, and the National Cancer Institute Cancer Center directory continue to be the best starting points for treatment resources, clinical trial information, and support programs.

Sources

Primary publication: Dent RA, Shao Z, Schmid P, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Annals of Oncology. 2026 Apr 3. doi:10.1016/j.annonc.2026.03.008. PubMed PMID: 41937088.

OncLive Phase 3 results: TROPION-Breast02 Data Support Dato-DXd as New First-Line SOC in Triple-Negative Breast Cancer. OncLive. April 2026.

OncLive Priority Review: FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy. OncLive. 2026.

OncLive panel discussion: Findings for Frontline Dato-DXd From TROPION-Breast02 in Immunotherapy-Ineligible TNBC. OncLive. May 2026.

OncoDaily safety summary: Datopotamab Deruxtecan Improves PFS and OS in First-Line Advanced TNBC in TROPION-Breast02. OncoDaily. April 2026.

Cancer Nursing Today: Datopotamab Deruxtecan Expands First-Line Treatment Options in Metastatic TNBC. May 2026.

CancerNetwork overview: How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research. CancerNetwork. May 2026.

AstraZeneca Priority Review announcement: DATROWAY granted Priority Review in the US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy. AstraZeneca. 2026.

TROPION-Breast01 context: FDA approves datopotamab deruxtecan for HR+/HER2- breast cancer. FDA.gov. January 2025.

Patient resources: NCI Cancer Center directory | Susan G. Komen | TNBC Foundation

FDA approval announcement: FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer. FDA.gov. May 22, 2026.

AstraZeneca/Daiichi Sankyo press release: DATROWAY approved in the US as first TROP2-directed ADC for 1st-line treatment of patients with metastatic TNBC. businesswire.com. May 22, 2026.

PharmExec approval coverage: FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates. pharmexec.com. May 2026.

AJMC approval coverage: Datopotamab Deruxtecan Wins First-Line FDA Approval for Immunotherapy-Ineligible Triple-Negative Breast Cancer. ajmc.com. May 2026.

Healio approval coverage: Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer. healio.com. May 2026.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. The TNBC indication for Datroway was approved under accelerated approval; continued approval may be contingent upon confirmatory trial results. Treatment decisions for metastatic TNBC should be made in close consultation with a qualified oncologist who can account for your individual diagnosis, treatment history, and tumor biology.

May 28, 2026

A New AI Tool Can Help Predict Which Breast Cancer Patients Can Skip Chemotherapy. The FDA Just Cleared It.

Chemotherapy works. For many women with breast cancer, it meaningfully reduces the risk that cancer will return. But chemotherapy also causes real harm: nausea, fatigue, increased infection risk, potential cardiac effects, nerve damage, and in some cases long-term consequences that persist years after treatment ends. For decades, oncologists have known that some women with early-stage breast cancer receive chemotherapy even though their tumor biology would never have threatened them with a recurrence. They endure months of treatment and its side effects for a benefit that, statistically, would not have materialized.

The challenge has always been identifying those women reliably, at the time of diagnosis, before any treatment has started. Existing tools like Oncotype DX and MammaPrint already attempt this, but they require separate molecular testing, come with turnaround times of several days, and cost thousands of dollars. The question the field has been working toward: can AI read a standard pathology slide, combine that with basic clinical data, and produce reliable risk stratification at the point of diagnosis, using materials that already exist?

On May 6, 2026, the FDA cleared ArteraAI Breast (Artera) for exactly that purpose. It is the first FDA-cleared digital pathology-based risk stratification tool for breast cancer. The answer, based on validated clinical trial data, is yes.

🔗 Also on HED: AI-Supported Mammography Just Got Its Strongest Evidence Yet This post is part of an ongoing HED series on artificial intelligence in women’s cancer care. Our previous post covered the landmark MASAI trial, which showed AI-supported mammography detected more cancers with no increase in false positives in a 105,000-woman randomized controlled trial.

Who ArteraAI Breast Is For

ArteraAI Breast is cleared for patients with early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancer. This is the most common breast cancer subtype, accounting for approximately 70% of all breast cancer diagnoses. The HR+/HER2- designation means the tumor is driven by estrogen or progesterone signaling and does not overexpress HER2. Standard treatment for early-stage disease in this group includes surgery, radiation, endocrine therapy (hormonal treatment), and, depending on risk, chemotherapy.

The decision about whether to add chemotherapy to endocrine therapy is the key clinical question for most of these patients. Women with clearly high-risk tumors, based on size, lymph node involvement, and grade, typically receive chemotherapy. Women with clearly low-risk disease typically receive endocrine therapy alone. But a substantial middle group sits in ambiguous territory, where the right answer is not obvious from standard pathological features alone. This is precisely the population ArteraAI Breast is designed to help.

How ArteraAI Breast Works

The tool uses multimodal artificial intelligence (MMAI), a term that describes AI systems that combine multiple types of data rather than analyzing a single input. In this case, the two inputs are a digitized histopathology image and patient clinical variables.

The pathology slide input

When a breast tumor is surgically removed, tissue samples are processed, embedded in paraffin wax, sliced very thin, stained with standard dyes (hematoxylin and eosin, or H&E), and placed on glass slides. A pathologist reviews these slides under a microscope to assess tumor grade, cell type, and other features. For ArteraAI Breast, the same slides are digitally scanned at high resolution, creating whole-slide images that the AI analyzes. No additional staining, no additional tissue processing, and no additional cost for sample preparation.

The clinical variables input

Alongside the digitized image, the system incorporates standard patient clinical data such as age, tumor size, nodal status, and grade. This multimodal approach allows the AI to recognize patterns across both the visual features of the tumor tissue and the clinical context, producing a composite risk score that neither input alone could generate as accurately.

The output

ArteraAI Breast generates a numerical risk score that provides prognostic information on the likelihood of distant metastasis. Using a predefined risk score cutoff, patients are stratified into low-risk and high-risk groups. Artera reports that results are available within one to two days of receiving the digitized sample, and the test produces no inconclusive results based on insufficient tissue, which is a meaningful practical advantage over some existing molecular assays.

How does this differ from Oncotype DX and MammaPrint? Oncotype DX (Genomic Health/Exact Sciences) and MammaPrint (Agendia) are the two most widely used molecular risk stratification tests for early-stage HR+/HER2- breast cancer. Both analyze gene expression patterns in tumor tissue and generate recurrence risk scores. Both are validated in large clinical trials (TAILORx for Oncotype DX, MINDACT for MammaPrint) and incorporated into NCCN and ASCO guidelines. The key practical differences with ArteraAI Breast are the input type and the infrastructure required. Oncotype DX and MammaPrint require tumor tissue to be processed with specialized molecular assays, shipped to central laboratories, and analyzed using RNA extraction and gene expression profiling. This adds cost, processing time, and requires specific tissue handling. ArteraAI Breast uses the standard H&E pathology slides that every pathology laboratory already produces as part of routine diagnosis, digitized on equipment increasingly common in pathology labs. ArteraAI Breast does not yet have the decades of clinical validation data behind Oncotype DX and MammaPrint. The tools serve complementary rather than competing roles in the current clinical framework. As the evidence base for ArteraAI grows, the field will develop clearer guidance on how these tools should be used together or sequentially.

The Clinical Trial Data Behind the Clearance

The FDA clearance is supported by data from two clinical trials, both presented at the 2025 San Antonio Breast Cancer Symposium (SABCS).

ABCSG 8 trial: postmenopausal patients, 10-year outcomes

In a presentation evaluating postmenopausal patients from the ABCSG 8 trial (NCT00291759), the MMAI platform stratified patients into three risk groups with the following 10-year distant metastasis-free survival rates:

Risk group	10-year DMFS	Clinical meaning
Low risk	Approximately 95%	Very low likelihood of cancer spreading to distant organs within 10 years
Intermediate risk	Approximately 89%	Moderate likelihood; additional therapy discussion warranted
High risk	Approximately 77%	Substantially elevated risk; chemotherapy benefit more likely to outweigh harm

NSABP B-20 trial: chemotherapy benefit in high-risk patients

A separate presentation evaluated patients with node-negative, HR-positive disease from the NSABP B-20 trial. In the subset of patients the MMAI tool classified as high-risk, chemotherapy produced a 52% relative decrease in 10-year distant metastasis rates compared with no chemotherapy. This is the predictive component of the tool: not just identifying who has high recurrence risk, but identifying who actually benefits from adding chemotherapy.

The 52% figure is clinically significant. It suggests the AI is not merely sorting patients by overall risk level but identifying the biologically distinct group for whom chemotherapy’s mechanism of action provides substantial additional protection beyond endocrine therapy alone.

Both datasets were presented at SABCS 2025 rather than published in a peer-reviewed journal at the time of FDA clearance. Peer-reviewed publication of the full analyses will be an important milestone for establishing this tool’s position in clinical guidelines.

“Patients and clinicians need to understand their risks for recurrence and decide which treatments will be the most effective, thereby avoiding both undertreatment and overtreatment.” — Calvin Chao, MD, Vice President of Medical Science, Artera. Medical News Today, May 2026.

The Bigger Picture: AI Is Changing How Oncologists Make Treatment Decisions

ArteraAI Breast is part of a broader pattern in oncology: artificial intelligence tools are moving from research into regulated clinical practice, with specific cleared or approved uses that change how clinicians gather and act on diagnostic information. The FDA clearance for ArteraAI Breast came in the same month as several other landmark AI decisions in women’s health, reflecting a maturation of the regulatory pathway for these tools.

The clinical and societal significance of AI in this specific context is worth stating plainly. Approximately 300,000 women are diagnosed with breast cancer in the United States each year. A substantial fraction have early-stage HR+/HER2- disease, the exact population for whom the chemotherapy decision is genuinely uncertain. Any tool that reliably identifies the women who can safely avoid chemotherapy reduces harm at scale, not just for individual patients.

The challenge the field now faces is integration. Hospitals need digital pathology scanning infrastructure. Clinicians need to understand what the score means and how to incorporate it alongside existing tools. Guidelines from NCCN, ASCO, and other bodies will need to address how ArteraAI fits alongside Oncotype DX and MammaPrint in clinical decision-making. None of this happens automatically after FDA clearance.

What Patients with Early-Stage HR+/HER2- Breast Cancer Should Know

Is this tool available at my hospital?

ArteraAI Breast received FDA clearance on May 6, 2026. Commercial availability is being rolled out now. Not every hospital or pathology laboratory will have access immediately. Availability depends on whether the institution has digital pathology scanning capability and whether they have contracted with Artera. It is reasonable to ask your oncologist or breast surgeon whether their center uses ArteraAI or a similar digital pathology tool.

Does this replace Oncotype DX or other genomic tests?

Not currently. Oncotype DX and MammaPrint have more extensive published evidence and are incorporated into major clinical guidelines. ArteraAI Breast is a new cleared tool with promising validation data. The two types of tests are based on different biological signals and may provide complementary information. Your oncologist will determine which risk stratification approach is most appropriate for your specific situation.

What does a low-risk result mean in practice?

A low-risk score from ArteraAI Breast indicates that the tumor’s pathological features and your clinical characteristics, as analyzed by the AI, suggest a low probability of distant metastasis. It does not guarantee that cancer will not return. What it does provide is additional evidence that can inform the conversation with your oncologist about whether chemotherapy is likely to offer you a meaningful benefit. That conversation still requires individual clinical judgment, not just a test result.

What limitations exist?

The supporting data was presented at a conference, not yet published in a peer-reviewed journal. Peer-reviewed publication with full methodology and statistical detail is the standard against which tools are evaluated by guidelines committees. This is expected to follow, and the FDA clearance was granted on the basis of this data, but it is a relevant caveat.
The tool stratifies into low and high risk, not a single continuous recurrence score. Some other tools provide a continuous score with a range of risk thresholds. The binary or three-tier stratification provides clear decision support but may not capture the full spectrum of risk for every individual patient.
Long-term prospective data specifically tracking ArteraAI-guided treatment decisions and their outcomes does not yet exist. The existing validation uses retrospective data from prior trials. Prospective evidence that patients guided by ArteraAI scores have better outcomes than those guided by standard assessment alone will take time to accumulate.

The bottom line

For a large number of women with early-stage HR+/HER2- breast cancer, chemotherapy is a treatment they could safely skip. Identifying those women reliably at diagnosis has always been the challenge. ArteraAI Breast is a new, FDA-cleared tool that uses the pathology slide already generated during standard cancer diagnosis to produce a risk score within one to two days, with no additional tissue processing required. The clinical trial data supporting the clearance is promising, particularly the 52% reduction in distant metastasis with chemotherapy in the tool’s high-risk group. The limitations around peer-reviewed publication and prospective outcome data are real and worth tracking. For patients currently navigating a breast cancer diagnosis, the most useful next step is a conversation with a breast oncologist about which risk stratification tools are appropriate for your specific tumor and clinical profile. The National Cancer Institute Cancer Center directory and the Susan G. Komen helpline are strong starting points for connecting with specialized breast oncology care.

Sources

Artera FDA clearance press release: Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer. May 6, 2026.

CancerNetwork: FDA Clears AI Stratification Tool in HR+/HER2- Invasive Breast Cancer. CancerNetwork. May 2026.

ITN Online: FDA Clears AI Digital Pathology Risk Stratification Tool in Breast Cancer. Imaging Technology News. May 6, 2026.

Femtech Insider: Artera Receives FDA Clearance for AI-Powered Breast Cancer Risk Stratification Tool. Femtech Insider. 2026.

Medical News Today: FDA-cleared AI risk tool could help guide breast cancer therapy. Medical News Today. May 2026.

Medical Device Network: Artera hits US first with pathology-based breast cancer risk tool’s clearance. May 2026.

BusinessWire: Artera Receives U.S. FDA Clearance for ArteraAI Breast. BusinessWire. May 6, 2026.

LabMedica: FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification. LabMedica. 2026.

ABCSG 8 trial: Austrian Breast and Colorectal Cancer Study Group Trial 8 (NCT00291759).

NSABP B-20 trial: National Surgical Adjuvant Breast and Bowel Project B-20. ClinicalTrials.gov.

HED internal post (MASAI): AI-Supported Mammography Just Got Its Strongest Evidence Yet. Health Evidence Digest.

Disclaimer: Health Evidence Digest provides general information about FDA clearances and health research for educational purposes. This content is not a substitute for professional medical advice. ArteraAI Breast is a risk stratification aid and is not intended to replace clinical judgment. All treatment decisions for breast cancer should be made in consultation with a qualified oncologist.

May 13, 2026

AI-Supported Mammography Just Got Its Strongest Evidence Yet. Here Is What the Landmark MASAI Trial Found.

📌 The essentials The MASAI (Mammography Screening with Artificial Intelligence) trial, published in The Lancet on January 31, 2026, is the largest randomized controlled trial of AI in any cancer screening program ever conducted. In 105,934 women across Sweden, AI-supported mammography improved screening sensitivity from 73.8% to 80.5% (p=0.031) while specificity remained identical at 98.5% in both groups (p=0.88). The interval cancer rate, the gold standard measure of missed cancers between screenings, was lower in the AI group: 1.55 versus 1.76 per 1,000 women screened. AI reduced aggressive and advanced interval cancers specifically, including fewer non-luminal A (more aggressive) tumors in the AI group (43 versus 59). And AI triaged 44% of scans to single-reader review without loss of accuracy, directly addressing radiologist workforce constraints. This post covers what the trial measured, how the AI worked, what the numbers mean in practice, and what remains open.

Every year in the United States, roughly 40 million mammograms are performed. Each one is read by at least one radiologist, and in many countries including Sweden, by two. Reading is time-consuming, cognitively demanding, and subject to the same variation in judgment that affects every human visual task. Radiologists miss some cancers. They also flag some findings as suspicious that turn out to be benign, sending women back for additional imaging or biopsies they did not need.

The promise of artificial intelligence in mammography is that it could do better on at least one of those problems without making the other worse. Catch more cancers while generating no more unnecessary callbacks. Or reduce the reading burden on an overstretched radiologist workforce while maintaining safety. Ideally, both.

The MASAI trial, published in The Lancet on January 31, 2026, is the first and largest randomized controlled trial of AI in any cancer screening program. It enrolled over 105,000 women in Sweden and ran from April 2021 to December 2022. The full results answer the central questions directly: AI-supported mammography caught more cancers and produced no increase in false positives.

The Measure That Matters Most: What Is an Interval Cancer?

Before getting into the numbers, it helps to understand what the MASAI trial was primarily designed to measure. The primary endpoint was not detection rate during screening. It was the interval cancer rate.

An interval cancer is a breast cancer diagnosed between scheduled screening rounds, meaning after a mammogram that came back negative. These are the cancers the screening missed. A woman left the screening appointment with a clean bill of health and developed a symptomatic cancer before her next scheduled appointment. Interval cancers tend to be more aggressive than screen-detected cancers because aggressive tumors grow faster and are more likely to become apparent between screening rounds rather than at the next scheduled scan.

Reducing the interval cancer rate is the gold standard test of whether a screening program improvement is real. It means the test is catching more of the dangerous cancers before they become symptomatic, not just generating more detections of indolent findings that would never have harmed the patient.

The MASAI Trial: Design and What AI Was Actually Doing

The MASAI (Mammography Screening with Artificial Intelligence) trial (NCT04666026) was a randomized, controlled, single-blinded, population-based screening accuracy trial conducted across three regions in Sweden. Enrollment ran from April 2021 through December 2022. A total of 105,934 women were randomly assigned, with 105,915 eligible for the final analysis: 53,043 in the AI-supported group and 52,872 in the standard double-reading group.

The median age in both groups was approximately 54 years, consistent with a population-based screening program. Sweden screens eligible women every 1.5 to 2 years, or annually for those at higher risk.

How the AI worked in this trial

The AI system played two roles in the intervention arm. First, it triaged each mammogram scan for single or double reading by radiologists. Scans the AI assessed as lower risk were forwarded to a single radiologist read rather than the standard two-reader process. Scans assessed as higher risk received double reading with AI detection support. Second, in double-read cases, the AI highlighted suspicious areas on the images to assist the radiologists reviewing the scan.

The AI system used in MASAI was trained, validated, and tested on over 200,000 mammography scans before deployment. The control arm received standard double reading by two radiologists without any AI involvement.

The Results: What the Trial Found

Outcome	AI-supported	Standard double-read
Sensitivity	80.5% (95% CI 76.4 to 84.2%)	73.8% (95% CI 68.9 to 78.3%)
p-value for sensitivity	p=0.031	Reference
Specificity	98.5% (95% CI 98.4 to 98.6%)	98.5% (95% CI 98.4 to 98.6%)
p-value for specificity	p=0.88 (no difference)	Reference
Interval cancer rate (per 1,000)	1.55 (95% CI 1.23 to 1.92)	1.76 (95% CI 1.42 to 2.15)
Invasive interval cancers	75	89
T2+ stage interval cancers	38	48
Non-luminal A interval cancers	43	59
Reduction in radiologist workload	44% of scans routed to single-read	All scans double-read

Source: Gommers J et al. The Lancet. 2026;407(10527):505-514. doi:10.1016/S0140-6736(25)02464-X. PubMed PMID: 41620232.

The specificity finding is the critical reassurance

Sensitivity is the ability to detect cancer when it is present. Specificity is the ability to correctly clear patients who do not have cancer. The two are often in tension: systems designed to catch more cancers tend to generate more false alarms. The MASAI finding that specificity was identical at 98.5% in both groups (p=0.88) is therefore one of the most important numbers in the entire dataset. AI caught more cancers without generating more unnecessary callbacks or biopsies. That is the combination the field has been working toward.

What the interval cancer characteristics tell us

The numbers behind the 12% reduction in interval cancers are worth examining carefully. Women in the AI-supported group had fewer interval cancers that were invasive (75 versus 89), fewer that had reached T2 or larger size (38 versus 48), and fewer that were non-luminal A subtype (43 versus 59). Non-luminal A tumors are the more aggressive breast cancer subtypes, including triple-negative and HER2-positive cancers. Their reduction is particularly meaningful because these are the cancers where early detection makes the biggest difference to survival.

The lead author of the MASAI trial, Dr. Kristina Lang of Lund University’s Division of Diagnostic Radiology, noted in the published report that the trial found AI-supported screening improves the early detection of clinically relevant breast cancers, reducing aggressive and advanced cancers diagnosed in between screenings. She also noted at the time of publication that AI adoption must be done carefully, with tested tools and continuous monitoring.

A Second 2026 Study in Nature Cancer: AI Increased Detection From 7.54 to 9.33 Per 1,000 Women

The MASAI results are part of a broader pattern of evidence building in 2026. A separate study published in Nature Cancer reported that AI-supported mammography increased cancer detection from 7.54 to 9.33 per 1,000 women screened. That translates to roughly 1.8 additional cancers detected per 1,000 women in a given screening round, or about 1 in 556 women screened gaining a detection they would have missed under standard reading.

The two studies use different endpoints and populations, so direct numerical comparison is limited. Together, they strengthen the evidence that AI-supported mammography reading improves cancer yield in real-world screening settings, not just in retrospective analyses of selected image archives.

What This Means for Patients Who Get Mammograms Today

Is AI reading my mammogram now?

Possibly. Several FDA-cleared AI systems for mammography assistance are in use at imaging centers and hospitals across the United States, including Transpara (ScreenPoint Medical) and iCAD. The specific AI tool used in the MASAI trial is not the only one commercially available, and the evidence base for individual products varies. The MASAI trial result tells us that when a well-validated AI system is integrated into a structured screening workflow, the combined result outperforms standard double reading. It does not automatically apply to every AI product on every platform.

Does AI replace the radiologist?

No. In the MASAI trial design, AI triaged scans to single or double reading by radiologists and highlighted suspicious areas for radiologist review. A radiologist made every final read. The AI reduced how many scans required two radiologists’ time and provided detection support to the reader who reviewed each case. The result was a 44% reduction in the portion of radiologist reading time devoted to double reads, without loss of accuracy.

This matters for healthcare systems facing radiologist workforce shortages. The United States and many European countries have a well-documented shortage of breast imaging specialists. A technology that allows the same number of radiologists to safely read more scans without reducing quality addresses a real structural problem in cancer screening infrastructure.

Will AI increase false alarms?

The MASAI trial specifically answers this. Specificity was 98.5% in both groups and the difference was not statistically significant (p=0.88). This is a reassurance, not a trivial finding. An AI system that drove up the recall rate would expose women to unnecessary imaging anxiety and follow-up procedures. Maintaining specificity while improving sensitivity is the combination that makes AI integration clinically viable rather than just mathematically impressive.

What interval cancers found in the study tell us about AI and aggressive tumors The 12% reduction in interval cancers in the AI arm is the most clinically meaningful finding for patients who actually get mammograms. Interval cancers are the ones that grow between screenings and become symptomatic before the next scheduled appointment. They tend to be more aggressive precisely because aggressive tumors grow faster. The MASAI data specifically showed the AI arm had fewer T2-or-larger interval cancers (38 versus 48) and fewer non-luminal A tumors (43 versus 59). Non-luminal A cancers are the harder-to-treat subtypes, including triple-negative and HER2-positive disease. Reducing the interval rate for these subtypes, not just for all cancers in aggregate, is what the trial’s authors describe as clinically relevant improvement. The benefit of higher sensitivity was consistent across age groups and breast density categories. Women with dense breast tissue, who are often told that mammography is less reliable for them, saw the same relative benefit from AI support as women with non-dense tissue.

What the Study Does Not Tell Us

The MASAI results are strong and the trial design is rigorous. Honest presentation of the evidence also requires naming what remains open.

This trial used one specific AI system. The results apply to the validated tool used in MASAI. There are multiple AI mammography products on the market with varying levels of clinical evidence behind them. FDA clearance for a device does not automatically mean its performance matches the MASAI AI system in this structured workflow.

Long-term survival data is not yet reported. The trial measured interval cancer rates and tumor characteristics, not survival outcomes. Whether the improved early detection translates into reduced breast cancer mortality over 10 to 20 years is the most important unanswered question. Based on what we know about how interval cancer rates relate to mortality in breast screening, the expectation is that it does, but long-term data from this cohort will be needed to confirm.

The trial was conducted in Sweden. Sweden has a national, population-based screening program with standardized protocols. Results may differ in healthcare systems with more fragmented screening delivery, different population characteristics, or different baseline double-reading rates.

Not all AI reads improve on human performance equally. A secondary analysis of the trial noted that the sensitivity improvement applied to invasive cancers but not to in-situ cancers specifically. Understanding which cancer types AI improves detection for, and which it does not, matters for interpreting the clinical impact.

Practical Guidance for People Due for a Mammogram

If you are due for a mammogram and have been putting it off, this study does not change the recommendation to screen. It strengthens it. Current American Cancer Society guidelines recommend annual mammograms starting at age 40 for average-risk women.

If your imaging center uses AI-assisted reading, it is reasonable to ask which system they use and whether it has been prospectively validated in clinical trials, not just retrospective analyses.

If you receive a callback for additional imaging after a mammogram, that is not necessarily a sign something went wrong. Recall rates remained the same under AI-supported reading in this trial. Most callbacks do not result in a cancer diagnosis.

For women with dense breast tissue who have been told mammography is less sensitive for them: the MASAI data showed the AI benefit was consistent across breast density categories. That is an encouraging finding, though supplemental screening options remain a separate conversation to have with your provider.

Screening intervals have not changed based on this evidence. The MASAI results strengthen the case for regular mammography participation, not for altering how often you screen.

For related women’s health coverage on Health Evidence Digest, see our post on new 2026 cervical cancer screening guidelines that now allow self-collection for HPV testing, as well as our coverage of pembrolizumab becoming the first approved immunotherapy for ovarian cancer.

Sources

Primary publication: Gommers J, Hernstrom V, Josefsson V, et al. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study. The Lancet. 2026;407(10527):505-514. doi:10.1016/S0140-6736(25)02464-X. PubMed PMID: 41620232.

MASAI trial registration: NCT04666026. ClinicalTrials.gov.

ASCO Post coverage: Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate. The ASCO Post. February 2, 2026.

EurekAlert/Lancet press release: AI-supported mammography screening results in fewer aggressive and advanced breast cancers, finds full results from first randomized controlled trial. EurekAlert. January 29, 2026.

AJMC coverage: AI-Supported Mammography Caught More Cancers During Screening. AJMC. 2026.

Lund University press release: AI support in breast cancer screening: Fewer missed cancer cases. Lund University. January 30, 2026.

MASAI interim safety results (2023): Lång K et al. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. The Lancet Oncology. 2023;24(8):936-944.

MASAI AI detection analysis (2024): Lång K et al. Identifying normal mammograms in a large screening population using artificial intelligence. Lancet Digital Health. 2024. doi:10.1016/S2589-7500(24)00267-X

Patient resources: American Cancer Society mammography guidelines | National Cancer Institute | Dense Breast Info

Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content does not constitute medical advice and is not a substitute for consultation with a qualified healthcare provider. Mammography screening recommendations should be discussed with your physician based on your individual health history and risk factors.

Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content does not constitute medical advice and is not a substitute for consultation with a qualified healthcare provider. Mammography screening recommendations should be discussed with your physician based on your individual health history and risk factors.

May 12, 2026

The FDA Said Yes to One ESR1 Drug and No to Another. What That Tells Us About the Future of Targeted Breast Cancer Treatment.

📌 The essentials On April 30, 2026, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6 to 3 against the clinical benefit of switching to camizestrant (AstraZeneca) in patients with HR-positive, HER2-negative metastatic breast cancer upon detection of an emerging ESR1 mutation during first-line therapy, before radiographic disease progression. The vote was based on data from the SERENA-6 Phase 3 trial. One day later, on May 1, 2026, the FDA approved vepdegestrant (Veppanu, Arvinas/Pfizer) for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after prior endocrine therapy. Both decisions involve ESR1 mutations in the same general patient population. They reached opposite conclusions. This post explains why, and what the difference reveals about how the FDA evaluates evidence in precision oncology.

Within 24 hours in late April and early May 2026, the FDA’s approach to ESR1-guided breast cancer treatment produced two very different outcomes. On the same day that an advisory panel voted against approving camizestrant for a ctDNA-guided treatment switch before disease progression, vepdegestrant was on its way to full FDA approval for the same patient population at a later stage of treatment. Understanding why these two decisions went in opposite directions requires understanding exactly what each drug was asking the FDA to accept.

What ESR1 Mutations Are and Why They Matter

ESR1 mutations occur in the gene that encodes the estrogen receptor. In patients with hormone receptor-positive, HER2-negative breast cancer, the estrogen receptor is the primary driver of tumor growth, which is why endocrine therapies that block or degrade it form the backbone of treatment.

The problem is that treatment pressure on the estrogen receptor eventually selects for mutations that allow it to remain active even in the absence of estrogen. These ESR1 mutations are acquired, meaning they typically arise during treatment rather than being present at diagnosis. They are detected in approximately 40 to 50% of patients who progress on first-line endocrine therapy plus a CDK4/6 inhibitor. When they emerge, they signal developing resistance and predict poor outcomes on continued aromatase inhibitor-based therapy.

Liquid biopsy technology, specifically circulating tumor DNA (ctDNA) testing, can now detect these mutations from a blood draw, often before the tumor shows measurable growth on a scan. That capability is central to both of the regulatory stories described in this post, but in two very different ways.

Vepdegestrant: The Approval That Happened

On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who had disease progression following at least one line of endocrine therapy. The approval arrived more than a month ahead of the June 5 PDUFA date, a signal that the FDA’s review was straightforward.

The approval simultaneously authorized the Guardant360 CDx liquid biopsy as a companion diagnostic to identify patients with ESR1 mutations who are eligible for treatment.

What the VERITAC-2 Trial Showed

The approval was based on data from VERITAC-2 (NCT05654623), a global, randomized, open-label Phase 3 trial that enrolled 624 patients at 213 sites across 25 countries. Patients were required to have disease progression on one to two lines of endocrine therapy, including one line with a CDK4/6 inhibitor. They were randomized 1:1 to receive either vepdegestrant orally once daily or fulvestrant intramuscularly.

In the 270-patient ESR1-mutated subgroup that drove the approval, vepdegestrant reduced the risk of disease progression or death by 43% compared to fulvestrant, with a median progression-free survival of 5.0 months versus 2.1 months (hazard ratio 0.57; 95% CI 0.42 to 0.77; p=0.0001). Across the overall trial population, regardless of ESR1 status, the PFS benefit did not reach statistical significance (hazard ratio 0.83; p=0.07), which reinforces the importance of ESR1 mutation testing before treatment selection and underscores that this approval is strictly for the ESR1-mutated population. Overall survival data are still immature, with only 16% of deaths having occurred at the time of the PFS analysis.

The VERITAC-2 results were presented at the 2025 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine.

What Makes Vepdegestrant Mechanistically Different

Vepdegestrant is more than a new drug in an existing class. It is the first PROTAC (proteolysis-targeting chimera) to receive FDA approval for any indication, making this a landmark regulatory event beyond its breast cancer-specific context.

Traditional SERDs (selective estrogen receptor degraders) like fulvestrant and elacestrant work by binding the estrogen receptor and triggering its degradation. Vepdegestrant takes a different approach: it is a bifunctional molecule that simultaneously recruits the estrogen receptor on one end and a cellular protein-degradation machinery component called an E3 ubiquitin ligase on the other. By bringing these two proteins into proximity, it directs the cell’s own waste-disposal system to destroy the estrogen receptor completely rather than simply blocking it.

This catalytic mechanism means one molecule of vepdegestrant can degrade multiple copies of the estrogen receptor and is then recycled to degrade more. It eliminates the receptor rather than occupying it, which is mechanistically important when dealing with ESR1 mutations that cause the receptor to remain active even when blocked.

We covered the full PROTAC mechanism and the VERITAC-2 trial data in detail here. The May 1 FDA approval means that post is now confirmed, and the drug is commercially available.

What Patients Should Know About Vepdegestrant

Vepdegestrant (Veppanu) is an oral once-daily tablet taken with food at a dose of 200 mg. It is indicated for patients who have already progressed on at least one line of endocrine therapy, including a CDK4/6 inhibitor. ESR1 mutation testing with an FDA-authorized ctDNA assay such as Guardant360 CDx is required before starting treatment.

The FDA label includes warnings about QTc interval prolongation (a heart rhythm consideration that requires monitoring) and embryo-fetal toxicity. The most common adverse effects across the trial were musculoskeletal pain, nausea, fatigue, hot flashes, and headache. Patients should discuss the full safety profile with their oncologist.

Camizestrant: The Vote Against

The ODAC vote on April 30, 2026, addressed a very different question. AstraZeneca was not asking the FDA to approve camizestrant for patients who had already progressed. It was asking whether camizestrant should be approved for patients who had developed an ESR1 mutation in a ctDNA blood test but had not yet shown radiographic evidence of disease progression on their current treatment.

This is a fundamentally different clinical scenario, and the distinction is the reason the vote went against approval.

The SERENA-6 Trial Design

SERENA-6 (NCT04964934) enrolled patients with HR-positive, HER2-negative advanced breast cancer who were stable on first-line aromatase inhibitor plus CDK4/6 inhibitor therapy for at least six months. Every two to three months, patients had ctDNA testing using the Guardant360 CDx assay. When an ESR1 mutation was detected in the blood, patients who had no evidence of disease progression on imaging were randomized to either continue their existing therapy or switch to camizestrant 75 mg plus their CDK4/6 inhibitor.

The PFS results were numerically compelling. The median PFS was 16.0 months in the camizestrant arm versus 9.2 months in the continued-aromatase-inhibitor arm (hazard ratio 0.44; p less than 0.00001). By the conventional statistical measures, this looks like a large effect. The ODAC voted 6 to 3 against it anyway. Why?

Why ODAC Said No

The committee’s concerns centered on three interconnected problems with interpreting the trial’s results as evidence of clinically meaningful benefit.

The PFS time zero problem. In SERENA-6, progression-free survival was measured from the time of randomization, which occurred at ESR1 mutation detection rather than at the start of treatment. Patients in the control arm who were still on therapy at randomization were inevitably closer to their next progression event than patients who had just started a new drug. This creates a structural asymmetry in how PFS is measured across the two arms that is not a drug effect. FDA reviewers flagged this as a nonstandard PFS time zero that complicates interpretation.

PFS2 is confounded by the protocol design. PFS2 (time to progression on the next line of therapy) is sometimes used as a supporting endpoint to demonstrate that a PFS benefit translates downstream. In SERENA-6, patients in the control arm were switched to camizestrant upon progression, as specified in the protocol. This protocol-mandated switch means PFS2 cannot serve as an independent confirmation of benefit, because both arms ultimately received the same drug.

Overall survival is immature and uncertain. OS data at the time of the ODAC meeting were too early to be interpretable. Committee members noted that without a mature OS signal, and with the PFS data carrying the methodological concerns described above, there was insufficient evidence that the ctDNA-guided switch before progression meaningfully improved patient outcomes compared to simply switching at the time of standard radiographic progression.

One additional safety note that ODAC discussed: there is a signal of potential cardiac toxicity when camizestrant is combined with ribociclib, one of the CDK4/6 inhibitors used in the trial. This was not a primary reason for the negative vote, but it added to the committee’s caution.

The Conceptual Question at the Heart of Both Decisions

Camizestrant and vepdegestrant both target ESR1 mutations. Both are oral SERDs (camizestrant) or SERD-class agents (vepdegestrant). But they were asking the FDA to accept fundamentally different propositions.

Vepdegestrant asked: does this drug help patients after they have already progressed on prior therapy? This is a well-established clinical endpoint with clear time zero, an appropriate comparator (fulvestrant, which is the current standard), and a patient population that has a demonstrated unmet need. The answer was yes.

Camizestrant asked: should treatment be switched based on a molecular signal in the blood, before the patient shows any clinical or radiographic signs of progression? This is a newer paradigm in precision oncology called ctDNA-guided adaptive therapy, and the SERENA-6 trial was the first global registrational trial to test it. The FDA’s position, reflected in the ODAC vote, was that SERENA-6 did not adequately answer this question.

The comparison matters because it illustrates a distinction that runs through many recent oncology regulatory debates. A large PFS hazard ratio is not by itself sufficient evidence of clinical benefit if the design creates ambiguity about what is actually being measured. ODAC members were not questioning whether camizestrant is an active drug. Several acknowledged that the drug likely has meaningful anti-tumor activity. What they were questioning is whether the SERENA-6 trial design adequately demonstrated that switching before progression is better for patients than switching at progression, which is the standard approach.

What Happens to Camizestrant Next

An ODAC vote against clinical benefit does not automatically result in a formal FDA rejection, but it is a strong signal. Given that the FDA’s own reviewers raised similar concerns before the advisory committee meeting, approval of the specific indication tested in SERENA-6 is unlikely without additional data.

AstraZeneca has separate ongoing trials for camizestrant in different settings. The SERENA-4 trial is evaluating camizestrant in the first-line setting for HR-positive, HER2-negative advanced breast cancer, which is a different clinical question and regulatory submission. A negative ODAC vote on one trial in one specific indication does not preclude a different regulatory outcome for the same drug in a different setting.

What ctDNA-Guided Treatment Really Means for the Field

SERENA-6 was the first randomized registrational trial to test the concept of using a liquid biopsy molecular signal to guide a treatment switch before clinical progression. The ODAC vote does not close the door on this concept. It identifies what the evidence will need to look like for regulators to accept it.

The fundamental question is whether catching and responding to molecular resistance earlier than radiographic progression meaningfully changes patient outcomes. The biological rationale is plausible: treating a smaller, less heterogeneous tumor burden before the clone driving resistance has fully taken over should theoretically be advantageous. But biological plausibility and clinical proof are different things. The trial design challenges in SERENA-6 made it difficult for the committee to separate the drug’s effect from the structural features of the ctDNA-guided randomization approach.

Future trials in this space will likely need to address the PFS time zero issue directly, use OS or PFS2 endpoints that are not confounded by protocol-mandated switches, and potentially show head-to-head evidence that pre-progression switching outperforms standard progression-triggered switching. That is a harder evidentiary bar, but it is a consistent one. The FDA has applied similar rigor to other adaptive precision oncology designs.

For patients with HR-positive metastatic breast cancer and their oncologists, the practical takeaway is that ctDNA testing for ESR1 mutations is increasingly central to treatment decisions. The Guardant360 CDx approval as a companion diagnostic for vepdegestrant means ESR1 liquid biopsy testing is now both clinically actionable and reimbursement-supported in the context of that approved indication. Whether it will also be used to guide pre-progression switches remains an open question pending further evidence.

What to Ask Your Oncologist

If you have HR-positive, HER2-negative advanced or metastatic breast cancer and have progressed on prior endocrine therapy including a CDK4/6 inhibitor, ask whether ESR1 mutation testing has been done on a recent blood sample. If an ESR1 mutation is present, vepdegestrant (Veppanu) is now an approved option and should be part of the treatment discussion.

If you are currently stable on first-line aromatase inhibitor plus CDK4/6 inhibitor therapy, the ctDNA-guided pre-progression switch with camizestrant is not currently an approved approach based on the April 30 ODAC vote. Routine ESR1 monitoring during first-line therapy is likely to be discussed by your oncologist as evidence continues to develop, but it should not change your current treatment plan without a direct conversation with your care team.

For information on clinical trials evaluating newer approaches to ESR1-mutated breast cancer, ClinicalTrials.gov is the primary reference.

Sources

FDA approval of vepdegestrant: FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA.gov. May 1, 2026.

VERITAC-2 trial registration: NCT05654623. ClinicalTrials.gov.

Arvinas FDA approval announcement: Arvinas Announces FDA Approval of VEPPANU (vepdegestrant). GlobeNewswire. May 1, 2026.

Targeted Oncology vepdegestrant approval: FDA Approves Vepdegestrant for ESR1-Mutated ER+/HER2- Advanced Breast Cancer. Targeted Oncology. May 2026.

OncLive ODAC vote coverage: FDA ODAC Votes Against Clinical Benefit of Switching to Camizestrant in HR+ Breast Cancer After ESR1 Mutation Detection. OncLive. April 30, 2026.

CancerNetwork ODAC coverage: FDA ODAC Votes No to Camizestrant for HR+/HER2- ESR1 Advanced Breast Cancer. CancerNetwork. April 2026.

Targeted Oncology ODAC coverage: FDA’s ODAC Votes Against Camizestrant in Advanced Breast Cancer. Targeted Oncology. April 2026.

AstraZeneca press release on ODAC vote: Update on FDA Advisory Committee vote on camizestrant. AstraZeneca. April 30, 2026.

OncLive April breast cancer flashback: FDA Flashback: Breast Cancer Decisions and News From April 2026. OncLive. 2026.

SERENA-6 trial registration: NCT04964934. ClinicalTrials.gov.

ESR1 mutation background: ESR1 mutations in breast cancer. StatPearls. NCBI.

AACR Q1 2026 Approvals: FDA Approvals in Oncology: January-March 2026. AACR Cancer Research Catalyst. April 2026.

Disclaimer: Health Evidence Digest provides general information about FDA regulatory processes, clinical trial results, and oncology research for educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment. Vepdegestrant (Veppanu) is FDA-approved and commercially available; camizestrant is not approved in the indication discussed in this post. Treatment decisions for advanced breast cancer should be made in close consultation with a qualified oncologist who can evaluate your individual diagnosis, mutation status, and treatment history.

May 10, 2026

A First-of-Its-Kind Cancer Drug Is Heading Toward FDA Approval. What Is a PROTAC and What Could It Mean for Breast Cancer Treatment?

📌 Updated May 1, 2026: FDA Approval Confirmed The FDA approved vepdegestrant (Veppanu) on May 1, 2026, more than five weeks ahead of the June 5 PDUFA date. This post has been updated throughout to reflect the approval. For a companion analysis covering both this approval and the ODAC vote against camizestrant the day before, see: The FDA Said Yes to One ESR1 Drug and No to Another.

For most of the past decade, the standard treatment arc for ER-positive, HER2-negative metastatic breast cancer has followed a recognizable sequence. First-line CDK4/6 inhibitor plus endocrine therapy. Disease progression. A second endocrine therapy, often fulvestrant. Progression again. Options narrowing.

A significant portion of patients progressing on that arc carry a specific tumor mutation in the ESR1 gene that makes their cancer actively resistant to standard endocrine therapies. Their tumors have evolved to activate the estrogen receptor without estrogen. For these patients, the question is not whether the disease will progress but how much time and quality of life can be preserved between progression events.

Vepdegestrant (Veppanu), developed by Arvinas and Pfizer, was approved by the FDA on May 1, 2026. It is designed specifically for this population. What makes it scientifically distinctive is not just its efficacy data but the mechanism. Vepdegestrant is a PROTAC: a drug that destroys its target protein rather than blocking it. It is the first drug of this type ever cleared in oncology.

The ESR1 Mutation Problem: How Tumors Learn to Ignore Endocrine Therapy

ER-positive breast cancer is driven by estrogen signaling through the estrogen receptor, a protein encoded by the ESR1 gene. Standard endocrine therapies work by either suppressing estrogen production (aromatase inhibitors) or blocking estrogen from binding to the receptor (fulvestrant). This works well initially. The problem develops over time.

Under the selective pressure of prolonged endocrine therapy, tumor cells can acquire point mutations in the ligand-binding domain of ESR1, the region where estrogen normally attaches to activate the receptor. These mutations cause the receptor to adopt an active conformation even in the absence of estrogen. The tumor has effectively rewired itself to bypass the treatment. The cancer grows because it no longer needs the hormone the therapy is trying to suppress.

This is not a rare edge case. Studies show ESR1 mutations are present in approximately 20 to 40% of ER+/HER2- metastatic breast cancer patients who have received prior aromatase inhibitor therapy, and the prevalence increases substantially with treatment lines, reaching as high as 59% in ctDNA analysis of patients in later lines. The broad adoption of CDK4/6 inhibitors in combination with aromatase inhibitors as the first-line standard has actually accelerated ESR1 mutation emergence, because the CDK4/6 inhibitor extends the duration of aromatase inhibitor exposure and thus the selective pressure for ESR1 mutations.

Why ctDNA testing matters for this patient population ESR1 mutations are generally not present at initial diagnosis — they are acquired under treatment pressure. This means testing the primary tumor biopsy taken at diagnosis will miss them in most cases. Detection requires liquid biopsy (circulating tumor DNA, or ctDNA) testing on a blood sample taken after disease progression. ASCO and NCCN guidelines recommend ctDNA testing for ESR1 mutations in patients with ER+/HER2- advanced breast cancer progressing on endocrine therapy, because ESR1 mutation status now directly informs treatment selection. The FDA simultaneously approved the Guardant360 CDx as the companion diagnostic for identifying patients eligible for vepdegestrant. If you have ER+/HER2- advanced breast cancer and have not had ctDNA testing, discuss it with your oncologist.

What Is a PROTAC? The Chemistry Behind a New Era of Cancer Drugs

To understand what makes vepdegestrant different from everything that came before, it helps to understand how conventional targeted therapies work and where they fall short.

Most existing targeted therapies, aromatase inhibitors, kinase inhibitors, CDK4/6 inhibitors, work by occupying the active site of a target protein and blocking its function. The analogy often used is a key and a lock: the drug sits in the lock and prevents the key from working. The protein is inhibited but remains present.

There are two fundamental problems with this approach in cancer. First, tumors can develop mutations that change the shape of the binding site, so the inhibitor no longer fits. The protein is still there; it’s just not blocked anymore. Second, some cancer-driving proteins don’t have conveniently accessible active sites at all, making conventional inhibition impossible. These are sometimes described as “undruggable” targets, a category that has driven decades of failed drug development attempts.

The PROTAC approach: degrade instead of block

PROTAC stands for PROteolysis TArgeting Chimera. It is a bifunctional molecule: one end binds to the cancer-driving target protein (in vepdegestrant’s case, the estrogen receptor), and the other end recruits an E3 ubiquitin ligase. This ligase is part of the cell’s own protein disposal machinery, the ubiquitin-proteasome system. When both ends of the PROTAC connect their respective targets, the cell’s disposal machinery tags the cancer protein with ubiquitin chains. The tagged protein is then threaded through the proteasome, essentially a molecular shredder, and destroyed.

Once the protein is degraded, the PROTAC is released and can recruit the next copy of the target protein for destruction. This catalytic recycling means each PROTAC molecule can degrade multiple copies of the target, potentially making high drug concentrations less necessary. Because the mechanism destroys the protein rather than occupying its active site, resistance through active-site mutation is far harder. The tumor cannot mutate away from destruction the way it can mutate away from blockade.

Feature	Traditional inhibitor (e.g., fulvestrant)	PROTAC (vepdegestrant)
Mechanism	Binds to and blocks target protein function	Recruits cell’s own disposal machinery to degrade target protein entirely
Target protein after treatment	Present but inhibited	Eliminated
Resistance pathway	Active-site mutations allow escape	Harder to mutate away from degradation
Drug efficiency	Must maintain continuous occupancy (stoichiometric)	Each molecule can be recycled (catalytic)
Druggability range	Requires accessible active site	Can target proteins without conventional drug-binding pockets
Administration	Intramuscular injection (fulvestrant)	Oral, once daily (vepdegestrant)

The VERITAC-2 Trial: What the Data Shows and What It Doesn’t

The FDA approval is based on data from VERITAC-2 (NCT05654623), a global, randomized, open-label Phase 3 trial. It enrolled 624 patients with ER+/HER2- advanced or metastatic breast cancer whose disease had progressed on prior CDK4/6 inhibitor plus endocrine therapy. Patients were stratified by ESR1 mutation status and presence of visceral disease, then randomized 1:1 to receive vepdegestrant 200 mg orally once daily or fulvestrant 500 mg by intramuscular injection. VERITAC-2 data were presented at the 2025 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine.

Efficacy results

Endpoint	Vepdegestrant	Fulvestrant
ESR1-mutated subpopulation (n=270)
Median PFS (BICR)	5.0 months (95% CI 3.7 to 7.4)	2.1 months (95% CI 1.9 to 3.5)
Hazard ratio	0.58 (95% CI 0.43 to 0.78)	Reference
p-value	less than 0.001	—
Risk reduction	43%	—
Treatment ongoing at analysis	33%	12%
Overall population (ITT, n=624)
Median PFS (BICR)	3.8 months (95% CI 3.7 to 5.3)	3.6 months (95% CI 2.6 to 4.0)
Hazard ratio (ITT)	0.83 (95% CI 0.69 to 1.01)	Reference
p-value (ITT)	0.07, NOT statistically significant	—
Overall survival	Immature at analysis	—

Source: Hamilton E et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. NEJM. 2025. doi:10.1056/NEJMoa2505725

The ITT miss is the most important nuance in this dataset The VERITAC-2 trial had two primary endpoints: PFS in the ESR1-mutated subpopulation and PFS in the overall intent-to-treat (ITT) population. Vepdegestrant met the first. It did not meet the second: overall ITT PFS was 3.8 versus 3.6 months (HR 0.83, p=0.07), which missed statistical significance. This matters for how the FDA scoped the approval. The indication is specifically for patients with ESR1-mutated tumors, not all comers with ER+/HER2- advanced disease. The drug does not appear to add meaningful benefit in the absence of this mutation. This pattern has been seen before: elacestrant (Orserdu), the currently approved oral SERD for this population, similarly showed its benefit confined to the ESR1-mutated subgroup in the EMERALD trial. The biology makes sense: patients whose tumors don’t carry ESR1 mutations are progressing through other resistance mechanisms that ESR1-targeting drugs don’t address. The clinical implication is that biomarker testing is not optional here. ESR1 mutation status is the selection criterion.

Safety Profile: What the Trial Showed

Vepdegestrant was generally well tolerated, with no unexpected safety signals in VERITAC-2. The FDA label includes important warnings about QTc interval prolongation and embryo-fetal toxicity that clinicians and patients should be aware of.

Adverse Event	Vepdegestrant	Fulvestrant
Fatigue (all grade)	26.6 to 27%	16%
Elevated ALT (all grade)	14.4%	10%
Elevated AST (all grade)	14.4%	10%
Nausea (all grade)	13%	9%
Grade 3 or higher adverse events	23.4%	17.6%
Treatment discontinuation due to AEs	2.9%	0.7%
QTc prolongation	Signal present; routine monitoring required per label	Not a labeled concern
New or unexpected safety signals	None identified	—

The elevated liver enzyme findings (ALT and AST) were predominantly low-grade and did not commonly lead to discontinuation. Fatigue at 27% versus 16% is meaningfully higher than with fulvestrant and worth discussing with patients proactively. The QTc prolongation signal in the label requires routine electrocardiogram monitoring during treatment, particularly when vepdegestrant is used in combination with other QTc-prolonging agents. The 2.9% discontinuation rate due to adverse events, while slightly higher than fulvestrant’s 0.7%, remains low in absolute terms for a heavily pre-treated metastatic population.

Where Vepdegestrant Fits: The ESR1-Mutated Treatment Landscape

Vepdegestrant is not the first drug developed specifically for ESR1-mutated ER+ metastatic breast cancer, but it is the first PROTAC in this space. Understanding where it sits relative to elacestrant requires knowing the current options.

Drug	Class	FDA Status	Key Trial
Fulvestrant (Faslodex)	SERD (injection)	Approved, current standard	Multiple trials; no ESR1-specific indication
Elacestrant (Orserdu)	Oral SERD	Approved January 2023, ESR1-mutated ER+/HER2- MBC	EMERALD: PFS 2.8 vs 1.9 months (ESR1m), HR 0.55
Vepdegestrant (Veppanu)	Oral PROTAC ER degrader	Approved May 1, 2026, ESR1-mutated ER+/HER2- MBC	VERITAC-2: PFS 5.0 vs 2.1 months (ESR1m), HR 0.58

The natural comparison is to elacestrant, the only previously approved oral SERD for ESR1-mutated ER+ metastatic breast cancer. Elacestrant showed PFS of 2.8 versus 1.9 months in the ESR1-mutated population of EMERALD (HR 0.55). Vepdegestrant showed 5.0 versus 2.1 months (HR 0.58). The numerics look more favorable for vepdegestrant, but these are separate trials with different patient populations, different prior treatment histories, and different control arms. Cross-trial comparisons are unreliable and should not be used to conclude one drug is superior to the other. No head-to-head trial exists.

What the landscape now offers is two approved oral options in the ESR1-mutated second-line setting, with different mechanisms and safety profiles. The sequencing question — which drug to use in which patient, and what comes after progression on either — is one the field will be working through over the next several years as real-world experience accumulates.

For a detailed analysis of how the vepdegestrant approval compares to the same-day ODAC vote against camizestrant, and what both decisions reveal about ctDNA-guided treatment strategies, see our post: The FDA Said Yes to One ESR1 Drug and No to Another.

Beyond Vepdegestrant: Why a PROTAC Approval Matters for All of Cancer Medicine

The significance of vepdegestrant’s approval extends well beyond this particular drug and patient population. Dozens of PROTAC candidates are currently in clinical development for a range of cancers, and this first approval validates the entire platform in a way that decades of academic research could not.

The PROTAC approach is particularly promising for what oncologists call “undruggable” targets, proteins that drive cancer growth but don’t have accessible pockets for conventional inhibitors. Mutant KRAS, certain transcription factors, and specific fusion proteins have resisted decades of drug development attempts. PROTAC-based degradation sidesteps the binding-site requirement, potentially making these targets approachable for the first time.

In breast cancer specifically, ongoing trials are exploring vepdegestrant in combination with CDK4/6 inhibitors. The VERITAC-1 Phase 1/2 study established tolerability for the vepdegestrant plus palbociclib combination. If vepdegestrant demonstrates durable benefit in combination regimens, the scope of its utility could expand significantly beyond the current second-line monotherapy setting.

What This Means for Patients Right Now

Vepdegestrant (Veppanu) is now FDA-approved and commercially available. Here is what patients navigating ER+/HER2- metastatic breast cancer should know:

If you have ER+/HER2- metastatic breast cancer and have progressed on CDK4/6 inhibitor-based therapy: ask your oncologist whether your tumor has been tested for ESR1 mutations via ctDNA liquid biopsy. This is increasingly the standard of care and directly affects which therapies are appropriate. The Guardant360 CDx is the FDA-approved companion diagnostic for this indication.
If you already have an ESR1 mutation documented: both elacestrant (Orserdu) and vepdegestrant (Veppanu) are now approved options in this setting. Discuss with your oncologist which is appropriate for your situation.
If you are in earlier lines of treatment: vepdegestrant is specifically approved for patients who have already received CDK4/6 inhibitor plus endocrine therapy. It is not a first-line option.
Do not wait to have the ESR1 testing conversation. Whether or not you are currently considering vepdegestrant, ESR1 mutation status is clinically actionable today because of both approved agents.

The treatment landscape for ER+/HER2- metastatic breast cancer is evolving faster than at any point in the past decade. The key resources for staying current include NCCN Clinical Practice Guidelines, the Metastatic Breast Cancer Alliance, and Living Beyond Breast Cancer, which maintains patient-facing resources on ESR1 mutations, ctDNA testing, and treatment options in the endocrine-resistant setting.

Sources

FDA approval: FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA.gov. May 1, 2026.

NEJM primary publication: Hamilton E et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2505725

VERITAC-2 trial registration: NCT05654623. ClinicalTrials.gov.

Arvinas FDA approval announcement: Arvinas Announces FDA Approval of VEPPANU (vepdegestrant). GlobeNewswire. May 1, 2026.

AJMC approval coverage: FDA Approves Vepdegestrant for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer. AJMC. May 2026.

VERITAC-2 study design (PMC): VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. PMC11524203.

ESR1 mutation prevalence: Comprehensive genomic profiling of ESR1 in HR+/HER2- MBC. PMC11420341.

Nature Reviews Clinical Oncology: PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations. Nat Rev Clin Oncol. 2025. doi:10.1038/s41571-025-01062-6

Elacestrant FDA approval: FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated breast cancer. FDA.gov. January 2023.

Patient resources: NCCN Guidelines | MBC Alliance | Living Beyond Breast Cancer | Guardant360 CDx information

Disclaimer: Health Evidence Digest provides general information about clinical trials and FDA regulatory processes for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions for metastatic breast cancer should be made in close consultation with a qualified oncologist who can account for your individual diagnosis, tumor characteristics, and treatment history.

May 5, 2026